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ABSTRACT 
 
Title of research 
 “Prevalence and risk factors of peripheral arterial occlusive disease in adult HIV positive 
patients in Indian population– A hospital based, cross sectional study” 
 
Department: General Surgery 
Name of candidate: Dr.S.Suraj 
Degree and subject: MS General Surgery 
Name of guide: Dr. Sukria Nayak 
 
Background: HIV has been known to cause arterial occlusive disease by atherosclerotic and non-
atherosclerotic mechanisms.   The underlying pathophysiological mechanisms are not well studied.  
There are only limited studies assessing the prevalence and risk factors of peripheral arterial 
occlusive disease in this population.  
 
There are very few studies from the Indian subcontinent addressing this issue where the 
load of HIV is high. 
 
As we all know, the mortality and morbidity associated with this incurable condition is high.  
With availability of HAART (Highly active antiretroviral therapy), patients now live longer 
and presence of peripheral arterial occlusive disease is emerging as a clinically relevant 
problem.  Presence of advanced HIV disease with low CD4 count and low albumin are poor 
prognostic factors for operative or non-operative management of vascular disease in this 
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population.  Rates of limb amputation with advanced disease can be higher.  Detection at an 
early stage may help in instituting preventive measures which can help improve clinical 
outcome.  
 
This study mainly aims to determine the prevalence of peripheral arterial occlusive disease 
in this population using clinical features and Ankle Brachial Pressure Index (ABPI).  The 
clinical details will be recorded in a proforma. 
 
Methods: A prospective observational study was conducted in the department of General Surgery 
and Infectious Disease Training and Research Centre (IDTRC) in the Christian Medical College, 
Vellore from November 2012 to September 2014.   All consenting HIV positive patients eligible for 
the inclusion criteria were included in the study.    
Methodology involved:  explaining to the patient about details of study with the help of an 
information leaflet, obtaining informed consent and recruiting them into the study.  A direct 
interview based on a proforma covering demography, symptomatology (assessed with help 
of Edinburgh Claudication Questionnaire), clinical and laboratory parameters and risk 
factors under study was done.  Finally the primary outcome measurement using the 
screening tool (Ankle Brachial Pressure Index and or Toe pressure) and its documentation in 
the proforma was done.  Data entry was done into an excel sheet.  Statistical analysis was 
done using SPSS software.  Prevalence of peripheral arterial occlusive disease and the 
significant risk factors for the causation of same was identified. 
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Results:  A total of 403 HIV positive patients were recruited in to the study. Average age of study 
population was 41.45.  There were 238 males and 165 females (59.1% Vs 40.1%). Claudication was 
reported by 19 patients (4.7%). Out of these 19 patients, 5 patients had final evidence of peripheral 
arterial disease. Prevalence of peripheral arterial occlusive disease (PAOD) was found to be 7.69% (n 
= 31). Out of these, 17 were females and 14 were males.  3 patients had >25% reduction in the post-
exercise ABPI.  But all these patients already had an abnormal ABPI (<0.9). Use of protease inhibitors 
and the duration of its use were identified to be strongly associated with causation of PAOD in this 
population. Traditional risk factors like diabetes mellitus, tobacco use including smoking, 
hypertension, and dyslipidaemia were not identified as independent risk factors for PAOD in this 
particular population. Duration of HIV infection, overall duration of HIV treatment and CD4 count < 
300 were also found to be high risk factors for PAOD in this population, but did not attain statistical 
significance in multivariate analysis. 
 
Conclusion: Prevalence of peripheral arterial occlusive disease in HIV positive patients is high in 
comparison to the general population.  Traditional risk factors seem to be playing negligible role in 
the development of peripheral arterial occlusive disease in these patients.  Protease inhibitor use 
and duration of its use can be strongly associated with development of PAOD in this population. 
Hence drug regime has to be carefully selected. 
 
Keywords:  HIV, peripheral arterial occlusive disease (PAOD), Ankle Brachial Pressure Index 
(ABPI), Toe pressure, risk factors, HAART 
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HIV has been known to cause arterial occlusive disease by atherosclerotic and non-
atherosclerotic mechanisms.   The underlying pathophysiological mechanisms are not well 
studied.  There are only limited studies assessing the prevalence and risk factors of 
peripheral arterial occlusive disease in this population.  
 
There are very few studies from the Indian subcontinent where the load of HIV is high. 
As we all know, the mortality and morbidity associated with this incurable condition is high.  
With availability of HAART (Highly active antiretroviral therapy), patients now live longer 
and presence of peripheral arterial occlusive disease is emerging as a clinically relevant 
problem.  Presence of advanced HIV disease with low CD4 count and low albumin are poor 
prognostic factors for operative or non-operative management of vascular disease in this 
population.  Rates of limb amputation with advanced disease can be higher.  Detection at an 
early stage may help in instituting preventive measures which can help improve clinical 
outcome.  
 
Our study was mainly aimed at determining the prevalence of peripheral arterial occlusive 
disease in this population using clinical features and Ankle Brachial Pressure Index (ABPI).  
The clinical details will be recorded in a proforma. 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
Chapter 2 
 
 
 
 
 
Aim and Objectives of the study 
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AIM  
To assess the prevalence of peripheral arterial occlusive disease in adult HIV positive patients 
and identify other possible risk factors for the development of peripheral arterial occlusive 
disease in this population  
 
 
OBJECTIVES 
      PRIMARY OBJECTIVE  
To assess the prevalence of peripheral arterial occlusive disease in HIV positive adult patients      
aged >/= 18 years presenting to a tertiary care hospital of India during the time period 
December 2012 to September 2014 
              
      SECONDARY OBJECTIVE  
To identify the possible risk factors for development of peripheral arterial occlusive disease in 
study population  
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The acquired immunodeficiency syndrome (AIDS) is caused by Human Immune deficiency 
virus (HIV).  It is a lentivirus belonging to retroviridae family [1].  These are single stranded, 
positive sense, enveloped viruses carrying an RNA genome.  It causes immune system 
destruction by affecting various target cells and through various mechanisms [2].   
 
First AIDS cases were reported in the United States in 1981 among intravenous drug abusers 
and homosexual men [3].  These men were diagnosed with Pneumocystis Carinii 
pneumonia, which was then considered a rare opportunistic infection.  This infection was 
known to occur only in individuals with extremely compromised immunity [4].  Immediately 
following this incident, another set of homosexual men were diagnosed with a priorly rare 
cutaneous malignancy (Kaposi’s sarcoma) *5+.   These two incidents led to the development 
of various task forces being set up by the Centre for Disease Control (CDC) in USA which 
eventually led to the discovery of this virus.   
First known case of HIV in India was diagnosed by Suniti Solomon and others amongst 
female sex workers in 1986 [6].    
 
Currently about 33.4 million people are living with HIV/AIDS worldwide.  It was estimated 
that about 2.0-3.1 million people are living with HIV/AIDS in year 2006 in India [7].  A more 
recent survey by National AIDS Control Organisation (NACO) of India estimated that 2.39 
million Indians live with HIV/AIDS in India in 2008–09.   According to NACO, the prevalence of 
AIDS in India in 2011 was 0.27%, which is down from 0.41% in 2002 and 0.35% in 2006 [8].  
But in terms of individuals affected, India stands third in the world [9].   
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HIV and other lentiviruses are transmitted through various pathways including semen, blood 
and blood products, breast milk, vaginal secretions etc.  Once the virus gains entry into the 
target cell, virally coded reverse transcriptase enzyme acts on the RNA genome and 
converts it into a double stranded DNA virus. This viral DNA, through various pathways gets 
incorporated into the nucleus of infected target cells [10].  After this incorporation, it can 
either stay latent for period of time or start multiplying to infect other cells.  This depends 
on a various number of factors including the nutritional status of the patient. 
 
HIV infects various cells of importance in the immune system of humans, like the 
macrophages, dendritic cells and helper-T cells [11].  HIV leads to a reduction in total CD4+ T 
lymphocyte cells through different mechanisms [12, 13] 
- Induction of apoptosis of normal bystander cells 
- direct killing of infected target cells 
- CD8+ T lymphocyte mediated killing of target cells 
 
Two types of HIV have been identified so far: HIV-1 and HIV-2 serotypes.   
HIV-1 was the virus that was initially discovered.  It was initially termed as HTLV-III.  This 
serotype of HIV is the more virulent amongst the two, and is more infective and acts as the 
aetiological agent for majority of infections across the globe [14].   
 
There are various numbers of clinical manifestations of this viral infection described in 
humans.  This includes cardiovascular, cerebral, cutaneous involvements and various types 
of malignancies including sarcomas and lymphomas.   
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Substantial numbers of opportunistic infections are also associated with HIV infection.  
Opportunistic infections are defined as those infections developing in HIV patients, which 
are more prevalent or more severe due to the underlying immunosuppression [15].  
This includes Pneumocystis carnii pneumonia, Toxoplasma gondii encephalitis, 
Cryptosporidiasis, microsporidiosis, mycobacterium tuberculosis, mycobacterium avium 
complex disease, bacterial respiratory disease and bacterial enteric disease, histoplasmosis, 
coccidioidomycosis, aspergillosis, cytomegalovirus (CMV) disease, herpes simplex virus 
(HSV) disease, human herpesvirus-8 (HHV-8) disease and varicella-zoster virus (VZV) disease 
[15].   Among these, mycobacterium tuberculosis is a very common opportunistic infection 
seen in HIV positive patients in India and neighbouring nations.   
 
These opportunistic infections add onto the overall morbidity and mortality of patients 
living with HIV/AIDS.  A large number of hospital admissions are also being due to these 
opportunistic infections.  The cost involved in getting these infections treated also adds 
extra financial burden on an HIV positive patient. 
 
AIDS epidemic had a large impact on the economy and health of many nations including 
India.  AIDS related death increased rapidly during the 1980s.  Average survival time after 
HIV infection, if left unattended is estimated to be around 9-11 years [16].  But the life span 
of patients living with HIV has improved in the last two decades due to the introduction of 
anti-retroviral agents and its effective distribution.  But in parallel, the number of 
opportunistic infections arrived over the years.  And what killed the patient after the 
introduction of HAART were these opportunistic infections. 
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Peripheral arterial occlusive disease (PAOD) is a condition which refers to the occlusion of large 
arteries (excluding brain, coronaries or aortic arch) by various aetiologies [17].  It is most commonly 
seen in the lower limbs.  This can lead to various secondary effects, ultimately ending in limb loss 
and also in some cases, death.   
 
202 million people were living with peripheral arterial occlusive disease across the globe in 
2010.  This was about 20% higher compared to 2000 estimates.  About 70% of patients with 
PAOD were from the developing nations.  About 54.8 million were living in Southeast Asian 
countries with PAOD [18].  Overall prevalence of peripheral arterial occlusive disease in the 
general population is estimated to be 1% at the age of 50 years and 3% at the age of 60 
years [19].  Most of these data were based on western studies.  There are limited studies in 
India and other subcontinent nations, which looked into the disease burden and prevalence 
of this disease.  The Chennai Urban Population Study found an overall prevalence of 3.2% 
among south Indian population [20].  As the name suggests, the study was predominantly 
conducted in an urban setting and might not be the actual representation of the status of 
the disease in the country. 
 
The most common cause of peripheral arterial occlusive disease is atherosclerosis [21, 22]. And this 
has remained the single most common cause across all populations.  
Multiple other aetiologies are also being described, which includes [17] 
- inflammatory processes (like vasculitis) 
- embolism  
- thrombus formation  
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Peripheral arterial occlusive disease (PAOD) is classified according to Fontaine stages, as 
described by Rene Fontaine in 1950’s [23, 24]  
 Stage I: Asymptomatic, incomplete obstruction of the vessel 
 Stage II: Mild claudication pain in the limb 
 Stage IIA: Claudication distance >200 metres 
 Stage IIB: Claudication distance <200 metres 
 Stage III: Rest pain  
 Stage IV: Necrosis and/or gangrene tissues 
Rutherford had recently re-classified PAOD into four grades and seven categories: [24] 
 Grade 0, Category 0 -  Asymptomatic 
 Grade I, Category 1 -  Mild claudication 
 Grade I, Category 2 - Moderate claudication 
 Grade I, Category 3 - Severe claudication 
 Grade II, Category 4 - Rest pain 
 Grade III, Category 5 -  Minor tissue loss (limited ischemic ulcers) 
 Grade IV, Category 6 - Major tissue loss (gangrene or severe ischemic ulcers) 
 
Typically, endovascular or surgical interventions are reserved for Class III and higher. 
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 Risk factors for PAOD are multiple.  Major among them are: [25] 
 
- Old age (especially >50 years) 
- Male sex 
- Smoking or use of tobacco in any forms 
- Diabetes mellitus 
- Hypertension 
- Dyslipidemia 
- Obesity (BMI >30.0)  
- History of prior cardiovascular events 
- Family history of vascular disease/events  
 
Potential risk factors for PAOD include elevated levels of the following [26]: 
 
- Homocysteine 
- Lipoprotein-a 
- C-reactive protein (CRP) 
- Fibrinogen 
- Plasma viscosity 
- Apo-lipoprotein B 
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Smoking  
Tobacco in any form has been identified as the single most important modifiable risk factor 
of PAOD.  Smoking was identified as the leading modifiable risk factor for arterial occlusive 
disease after the Framingham study found out a significant longitudinal association between 
it and PAOD [27].  Smoking was also found to be responsible for major number of the PAOD 
cases in the National Health and Nutrition Examination Survey [28].  Various quality of life 
studies have shown a superior life quality for non-smokers living with PAOD than smokers 
[29].  Studies from Asia also have identified that PAOD is a common disease among geriatric 
population with almost 40% of them remaining asymptomatic. Smoking was identified as 
the major risk factor for PAOD in this study too, with a two-fold increased risk of PAOD 
among smokers compared to non-smokers [30].   
 
Increased risk of PAOD is also associated with the number and duration of smoking [18].  
There is a three-fold higher risk of developing PAOD in patients who have smoked for less 
than twenty five years, compared to non-smokers.  Among those who have smoked for 25 
years or more, this risk increases to about five-fold [31].   
 
In PAOD patients who smoke, the chance of being having another cardiovascular risk factor 
is also high [28].  Among diabetics, the risk of PAOD is increased by a further 50% if the 
patient had history of tobacco use in some form [26, 27].   
 
Smokers have about tenfold increase in relative risk for PAOD in a dose-related effect and 
they also tend to develop more PAOD rather than coronary or cerebro-vascular events [27].  
Smokers have also been found to have greater risk of developing symptomatic as opposed 
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to asymptomatic PAOD, in particular an increased risk of intermittent claudication.  They 
also experience symptoms about 10 years earlier than the non-smokers [32].   
 
About 80%-90% of lower extremity peripheral arterial occlusive disease patients are found 
to be current or reformed smokers [18, 26].  Observational studies have found that the risk 
of death, myocardial infarction, and amputation is substantially greater among smokers 
with PAOD.  Success rates of lower extremity interventional procedures (open or 
endovascular) for PAOD are low if the patient continues to smoke [25].   
 
Environmental exposure from second hand smoke also leads to endothelial damage, which 
acts as precursor to atherosclerosis and thereby to the development of PAOD. 
 
There are different mechanisms through which smoking leads to the development of 
peripheral arterial occlusion: 
All tobacco products contain a large quantity of nicotine.  Once a tobacco product is 
consumed, especially when smoked, nicotine gets rapidly absorbed into the circulation.  This 
stimulates the release of various neurotransmitters (epinephrine and norepinephrine) from 
their storage cells. These neurotransmitters bind to vascular smooth muscle cell receptors 
resulting in varying degrees of vasoconstriction. This effect is usually brought into 
equilibrium by the release of various vasodilators stored predominantly in the vessel wall 
(like nitric oxide).  But in tobacco users especially in smokers, there is a loss of this 
equilibrium due to reduced production of vasodilatation agents.   This leads to chronic 
repeat episodes of vasoconstriction [18]. 
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These effects have been demonstrated in various quantitative studies as well.  In non-
smoking healthy adults, the usual amount of vasodilatation which happens in the larger 
arteries of upper (brachial artery) and lower limb (femoral artery) are 11% and 4% 
respectively.  This is reduced to 4% and 0% respectively in young otherwise healthy smokers 
[33].   
 
Carbon monoxide in tobacco smoke has a greater affinity to haemoglobin than oxygen.  So 
whenever a person smokes, the levels of carboxy-haemoglobin in the blood rise in 
comparison to oxyhemoglobin. This leads to oxygen deprivation at the tissue level.  
Carbon monoxide also increases the viscosity of blood, thereby hindering the available 
oxyhemoglobin reaching the tissues [18].  The net result of all these is tissue hypoxia. And 
when it happens in a chronic setting, it ultimately leads to tissue ulceration and/or 
gangrene.   
 
Smoking also results in a hypercoagulable state, thereby helping in the formation of clots in 
the vascular system [18].   
 
Smoking can also lead to arterial occlusion in an indirect way by promoting atherosclerosis.  
This is initiated by endothelial damage secondary to the deleterious effects of various toxic 
chemicals in the tobacco. Damaged endothelial cells promote transfer of LDL cholesterol 
across the vessel wall, resulting in the formation of lipid plaques [34].   
 
Tobacco, particularly smoking also reduces the levels of the HDL cholesterol, which is 
considered as “good cholesterol” [34].  Tobacco smoke also can cause derangements in 
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other components of the lipid profile including a rise in triglyceride levels and total 
cholesterol levels.  
 
A particular disease in India, where smoking is a strong risk factor for development of PAOD 
is Buerger’s disease or Thrombangitis Obliterans (TAO).  TAO affects the small and medium-
sized blood vessels of the body including both arteries and veins [35, 43].  Tobacco in any 
form can be the risk factor and only about 5% of affected are non-smokers [18, 35].  This 
disease is commonly seen in young male patients who smoke.   
 
Tobacco, particularly smoking initiates an immune response in susceptible persons or 
unmasks an underlying coagulation defect.  This leads to an inflammatory reaction of the 
vessels including veins, arteries and even the adjoining nerves.  This is classically described 
as the “pan arteritis” of Buerger’s disease [18, 35, 43].  
 
Any intervention aimed at smoking cessation is vital in patients with Buerger’s disease.  This 
is due to the aetiological contribution of tobacco in the development of this disease. And on 
the same note, the outcome of patients who continues to smoke is grave even after the 
institution of other therapeutic tools [18, 35]. 
 
Diabetes mellitus  
Risk of developing PAOD among diabetics is related to the severity and duration of diabetes 
mellitus.  Diabetic patients have about 2-4 times increased risk of developing PAOD compared to a 
non-diabetic.  Diabetics who smoke have a greater risk of developing PAOD, and runs about 30% risk 
of an amputation in the next five years [26].  
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Diabetes causes endothelial cell function and vascular regulation abnormalities [26].   
Most important pathway by which diabetes affects the endothelium is by derangement of 
nitric oxide bioavailability. Nitric oxide act as a vasodilatation agent and it also prevents 
leukocyte-vascular wall interaction. It also prevents vascular smooth muscle cell 
proliferation and migration.  Peripheral activation of platelets is also prevented by nitric 
oxide.  Hyperglycaemia blocks the function of e-NOS which is located in the vascular 
endothelium.  This leads to the production of reactive oxygen molecules, which impairs the 
vasodilatory equilibrium in the endothelium. This oxidative stress is further amplified since 
the vascular endothelial cells (in comparison to other cells in the body) lack the down 
regulation of glucose transport triggered by high blood sugars [26].  
 
Insulin resistance also plays a major role in the loss of nitric oxide homeostasis [36].  One of 
the important mechanism by which insulin resistance disrupt the nitric oxide homeostasis is 
by the release of excess free fatty acids (FFAs).  Free fatty acids in turn cause various toxic 
effects on vascular homeostasis, ultimately resulting in loss of nitric oxide homeostasis.  This 
includes [37]: 
- formation of reactive oxygen molecules  
- protein kinase C (PKC) activation in the endothelium 
- Inhibition of phosphatidylinositol-3-kinase  
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Local rise in multiple pro-inflammatory substances (activator protein 1, nuclear factor- κB) 
combined with loss of nitric oxide homeostasis affects various leukocyte functions.  This 
includes enhanced neutrophil chemo taxis, more number of adhesions, and transmigration 
across the cell and transformation to “foam cells”.  The process of transformation to foamy 
cells is further enhanced by a higher oxidative stress at near the vascular endothelium [37]. 
Foam cell transformation is regarded as the earliest precursor cell of vascular atherogenesis. 
 
Dyslipidaemia  
 
Dyslipidaemia is well recognised as a major risk factor for any cardiovascular diseases including 
PAOD.  Low HDL cholesterol, high LDL cholesterol, elevated total cholesterol and triglyceride levels 
have been correlated well with development of PAOD.  
 
Dyslipidaemia correction by life style modifications and/or lipid lowering drugs has been found to 
reduce the rates of major cardiovascular events in the life term [25] 
 
Hypertension  
 
Hypertension is associated with an increased risk of developing PAOD, as well as in the further 
development of other major cardiovascular events [25]. Hypertension alone increased the risk of 
intermittent claudication for about 4 and 2.5 fold in men and women, respectively [25].  
Hypertension is commonly an associated risk factor in smokers and diabetics, and the combined 
effect of all these can be detrimental. 
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Obesity  
 
Obesity was strongly associated with elevated inflammation markers like C-reactive protein and 
fibrinogen, which are predictors for active atherosclerosis.   
 
The prevalence of metabolic syndrome was found to be more among PAOD patients than other 
cardiovascular diseases.  It was 58% in PAOD patients, 47% in abdominal aortic aneurysm (AAA) 
patients, 43% in cerebrovascular disease patients and 41% in coronary disease patients [38]. Each 5-
unit increase in body mass index among adult Israeli men resulted in about 24% greater risk of 
intermittent claudication among adult Israeli men, adjusted for smoking status and number of pack 
years [39].  
 
Body mass index and Wait to hip ratio are the two commonly used tools to define obesity.  A body 
mass index of >30 is defined as obesity [25].   
 
Obese patients were found to have a greater oxidative stress.  This leads to decreased nitric oxide 
bioavailability in the vascular endothelium.  This in turn leads to endothelial dysfunction & 
vasoconstriction, and thereby to the development of PAOD.   
 
In the Framingham Heart Study, body mass index was closely associated with systemic oxidative 
stress, as obtained by biochemical tests.  A decrease in the function of nitric oxide would also 
predispose to other cardiovascular disease risk factors such as hypertension [40] 
 
29 
 
A carefully taken detailed clinical history and thorough physical examination is required in 
the identification of patients with possible PAOD.  History should be taken in such a way so 
as to include: 
- risk factors 
- symptoms of claudication & claudication distance 
- rest pain 
- varying degrees of functional impairment/tissue loss 
- details of prior interventions 
- details of prior cardiovascular events 
- symptoms pertaining to other vascular system involvement   
Alternative causes for pain in the leg need to be carefully excluded.  A thorough walking 
history will help us elicit classic symptoms and its variations.  
 
The classical symptom of peripheral arterial occlusive disease is the “intermittent 
claudication pain” *21, 22].  Claudication is derived from Latin word “claudicatio”, which 
means “to limp”.  
 
Claudication pain is defined as a reproducible pain experienced in the muscles of 
calf/thigh/buttock, brought in by exercise (typically walking) and relieved immediately by 
rest [22].   
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It is classified by Boyd into four categories as described below [41]: 
Boyd’s classification of claudication 
 
Grade I – Patient develops pain on walking.  If he continues to walk, pain disappears.  
Grade I I – Patient develops pain on walking. If he continues to walk, pain persists.  But the 
patient can still walk with efforts. 
Grade I I I – Patient develops pain on walking. The pain compels the patient to take rest. 
 
Characteristic features of claudication pain [42] 
 
1. Claudication pain is brought on by exercise 
2. Claudication pain is relieved at rest 
3. Claudication pain is a cramp like pain felt over the musculature 
4. Claudication pain is almost always reproducible 
 
Importance of site of claudication pain [42] 
 
Site of claudication pain is an indicator to the level of arterial occlusion; 
SITE LEVEL OF OCCLUSION IN THE ARTERY 
Gluteal Iliac 
Thigh Femoral 
Calf Popliteal 
Foot Tibial 
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PAOD patients present with a large spectrum of symptoms, ranging from asymptomatic,  
intermittent claudication, rest pain, and non-healing ulcers and/or gangrene.  
 
A thorough physical examination should be carried out.  This includes: 
- Documentation of vital parameters 
- Body mass index or waist to hip ratio 
- Documentation of all peripheral pulses and its strength.   
- Checking for bruits in the common areas 
- Visual inspection of the foot and hands for dependent erythema, pallor on 
elevation, absence of hair growth, dystrophic toe nails, and cool, dry, fissured skin 
- Look for fissures, ulcerations, and presence of infections in the foot   
- Examination of cardiac system especially looking for murmurs 
 
Peripheral pulse documentation is of greater importance in patients suspected of having 
PAOD, and also in those patients without PAOD, but with a risk factor for the same (viz.DM).  
The character of pulse also needs to be noted (strong Vs weak Vs absent).   
 
Pulse documentation can have high degree of inter-observer variability, thereby resulting in 
false positive and false negative results.  Also it has to be remembered that about 8% 
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patients can normally have an absent dorsalis pedis artery pulsation and about 2% can have 
absent posterior tibial pulsations [26].  But absent pedal pulses felt by an experienced hand 
should always raise the suspicion of PAOD in any patient [26]. 
 
But among those with PAOD,  about 50% do not demonstrate any symptoms or have 
atypical symptoms, about 30% have “intermittent claudication”, and the rest have more 
severe forms of vascular occlusion [43] 
 
History and physical examination may miss those asymptomatic patients which forms a major 
number of patients living with PAOD.  
 
Patients are usually screened for the disease when they present with the symptoms or if the disease 
is clinically suspected (Eg: long standing diabetes).  In Indian scenario, patients often present in a 
complicated stage, which makes the limb salvage low. Hence it is very important to diagnose the 
disease at the earliest so that the interventions can be instituted at the earliest.  
 
Lower limb ischemia can be classified as functional or critical [44].  Functional ischemia develops 
when the arterial blood flow is normal at rest but gets deprived during an exercise.  This clinically 
presents as intermittent claudication. Critical limb ischemia is developed when this reduced blood 
flow results in reduced tissue perfusion at rest.  This is defined by the presence of rest pain or 
trophic changes in the peripheries.  Hence it is very important to differentiate between these two 
entities since the therapeutic indications and final prognosis of patients with PAOD is determined by 
this [44].   
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Lower limb ischemia can also be classified as acute or chronic [42, 44].   
 
Acute limb ischemia occurs due to sudden decrease in the blood flow to a limb, resulting in a 
potential danger to the viability of the peripheral tissue, and in some cases, threat to life as well. 
Limb hypo perfusion results in hypoxia which leads to acid base disturbances especially lactic 
acidosis and dyselectrolytemia. These in turn endangers various systemic functions of the body. 
Successful reperfusion may result in the release of highly toxic free radicals, further compromising 
these critically ill patients.  
 
Two common causes of acute limb ischemia are thrombosis or embolism [44, 45].  Embolic 
problems result in a severe ischemia in comparison to thrombosis, as the embolus typically lodges in 
a "virgin" vascular bed with no collateral circulation. On the contrary, thrombosis mostly occurs in 
those vessels which already harbour atheromatous narrowing, that have triggered the development 
of collateral circulation. The presence of these collaterals reduces the severity and rapidity of 
symptom development in such patients, especially when the “narrow” vessel advances to an 
“occluded” vessel.   
 
It is often difficult to distinguish an embolic occlusion from a thrombotic occlusion.  However there 
were few factors which point towards a possible embolic occlusion [42, 44]: 
- acute onset 
- history of embolic event 
- no prior history of intermittent claudication 
- known source of embolus, such as cardiac  
- normal pulses and doppler studies in the unaffected side 
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Generalized atherosclerosis leading onto thrombosis is the most common aetiology for acute 
occlusions of peripheral vasculature. The superficial femoral artery is the most common site of 
atherosclerotic narrowing. Aggressive use of bypass grafts has resulted in a greater number of 
patients presenting with acute limb ischemia.  
 
The clinical presentation is considered to be acute if it occurs within 2 weeks after symptom onset. 
Symptoms develop over a period of hours to days [42].  
 
Classical description of patients with acute vascular ischemia is represented by the "six Ps": pain, 
pallor, paralysis, pulse deficit, paraesthesia, and poikilothermia [42]. 
 
Severity of acute limb ischemia is classified according to Rutherford classification [45, 46]: 
Rutherford Classification of Acute Limb Ischemia 
Category I: Viable - no immediate limb threat 
               -   Sensory deficit – nil 
         -    Motor deficit – nil 
         -   Arterial doppler signals present, but typically monophasic + venous doppler signals   
Category IIA: Marginally threatened  
    -  Sensory deficit – minimal (e.g. toes involved) 
  -    No motor deficit – nil 
  -    Arterial doppler signals absent + venous doppler signals present  
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Category IIB: Immediately threatened  
- Sensory deficit with rest pain 
- Motor deficit - Mild to moderate 
- Arterial doppler signals present + venous doppler signals present 
Category III: Irreversible (major tissue loss with permanent nerve injury) 
            -     Sensory deficit – severe with complete anaesthesia 
            -     Motor deficit - Severe with paralysis or rigor 
            -     Arterial doppler signals absent + venous Doppler signals present 
Mortality rate and complications among patients who present with acute limb ischemia are 
high. Despite urgent revascularization interventions, amputation rate among hospitalised 
patients range from 10 to 15%.  1 year mortality rate after initial presentation is about 15 to 
20%, mostly from the underlying conditions that predisposed to acute limb ischemia [44]. 
 
The final impact of PAOD can be assessed by its rate of progression, whether the patient is 
symptomatic or asymptomatic and the presence of additional cardiovascular events associated. 
Majority of patients may remain stable with respect to the peripheral symptomatology during this 
five year period.  About 20% develop nonfatal major cardiovascular events (coronary or cerebral) 
and about 30% eventually die during the next five years after the diagnosis of PAOD [47].  About 
27% of patients with PAOD demonstrate symptom progression over a 5-year period. About 4% end 
up in varying degrees of limb loss over the same period.  Those patients who have critical limb 
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ischemia, the outcomes are not good.  About a third will end up with an amputation(s) and about a 
fourth will die within next 6 months [43, 47]. 
       
Patients with peripheral arterial occlusive disease (PAOD) has six times increased risk of death from 
coronary artery disease and three times increased risk of death from any other cause [48].  PAOD is 
a predictor of development of future cardiovascular mortality and morbidities including 
cerebrovascular accident and myocardial events [22, 25].   
 
About 63% of symptomatic PAOD patients have polyvascular disease.  PAOD patients over the age 
of 50 have a 68% and 42% incidence of coexistent coronary artery disease and cerebrovascular 
events respectively [26].   
 
In view of all these factors, the early diagnosis and intervention of peripheral arterial occlusion is 
extremely important; both with respect to the reduction of morbidity and mortality associated with 
the disease and also other cardiovascular diseases. 
 
Sensitivity and specificity of clinical examination in picking up peripheral arterial occlusive disease is 
low [25, 49].  In the absence of a femoral bruit, the presence of all lower limb pulses predicts a 
normal ABPI with good sensitivity. Most reliable finding in the palpation of pulses which point 
towards the presence of PAOD is the absence of posterior tibial artery pulsation.  This has a 
specificity of about 70% and a sensitivity of about 90% for identifying lower extremity peripheral 
arterial disease [49].  
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Patients with an abnormal vascular examination should undergo ankle brachial pressure index 
measurement. Absence of dorsalis pedis and posterior tibial artery pulsations in any patient, 
especially when associated with a femoral bruit should raise high suspicion for PAOD, and an ABPI 
should be ordered in such patients.   
 
There exists a large inter-observer variability in the clinical examination especially with respect to 
the palpation of peripheral pulses.  Hence various non-invasive, easy to perform, cost effective 
modalities have been developed over the years.  These modalities are being employed in as 
screening tools in various studies on PAOD.   
 
Having a claudication questionnaire with good sensitivity combined with a non-invasive test of 
reasonable sensitivity, and a good clinical examination can diagnose most of symptomatic and many 
asymptomatic peripheral arterial occlusive disease [25]. 
 
WHO/Rose’s questionnaire was the traditional questionnaire used in the past for identifying 
claudication.  It was developed in 1962 for use in large epidemiological surveys.  Rose’s questionnaire 
was found to have a sensitivity of 60-68% and specificity of 90-100% in large epidemiological studies 
[50]. Owing to the low sensitivity of this, the requirement of another screening questionnaire arose.  
Hence a modified version of it was developed – The Edinburgh Claudication Questionnaire (ECQ) 
(included as part of proforma).   
 
The ECQ was developed and validated as part of the Edinburgh Artery Study [50] which recruited 300 
participants presenting with leg pain. This has 91% sensitivity and 99% specificity for identifying true 
claudication which is considered the classical symptom of peripheral arterial occlusion [50]. Since 
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then, this questionnaire has been largely employed in various studies on PAOD across the globe.  One 
drawback of ECQ lies in the fact that it helps us in identifying only the symptomatic PAOD patients.  
About 50% patients with PAOD might not have any symptoms.  Hence this questionnaire needs to be 
accompanied by a sensitive screening tool so as to detect the asymptomatic PAOD patients as well.   
 
Angiography is considered the gold standard for diagnosis of peripheral arterial occlusive disease.  CT 
and MR angiography are the widely used modalities.  CT angiography has about 95% sensitivity and 
specificity in diagnosing significant stenosis in the vascular system [51].  CT angiography also gives a 
clear picture of the vessel wall and its adjoining structures.  It can detect in detail about the plaque 
characteristics, presence or absence of vessel wall calcification and ulceration.  Details about the 
presence of a thrombus can also be obtained.   In patients who have an in-situ stent, CT angiography 
can help detect restenosis and “stent fractures” [52].  
 
Major drawbacks of CT angiography are the use of contrast and thus the invasiveness.  In patients 
with renal failure or contrast allergies, one needs to be careful in ordering CT angiography as the 
diagnostic tool.  Also in comparison to MR angiography and duplex studies, there is radiation 
exposure and its hazardous effects including the future risk of malignancy.  CT angiography is 
intermediate in cost compared to MR angiography and is costlier than arterial duplex [52].  But 
nowadays most tertiary care centres harbour a CT machine making it possible to obtain angiography.   
 
MR angiography has many benefits over CT angiography for obtaining the peripheral arterial tree 
details. Most important of all these is the absence of radiation exposure.  Risk of contrast induced 
nephropathy is low in comparison to other angiographic modalities which use iodinated contrast 
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agents [53]. The sensitivity and specificity of MR angiography in detecting arterial stenosis reaches 
about 80–90% range [54].  
 
Performing angiography is costly, time consuming, cumbersome and invasive.  Hence in many 
populations, especially in developing countries where people are not affordable, it becomes  
impractical to use these modalities for a community screening program.  They can be used to confirm 
disease in clinically proven cases (absent or diminished pulses) or to diagnose clinically strongly 
suspected patients (classical intermittent pain/rest pain) with normal ABPI. 
 
Arterial duplex scan is another modality which can be used to confirm the presence of PAOD.  In 
addition to vascular anatomic details, it also provides information about the flow details within the 
vessels [55].  It can also give information about the level and extent of occlusion.  Another greater 
advantage is the non-invasiveness.  It has been widely used as a screening tool to decrease the 
necessity for invasive modalities especially in low income settings.  It is relatively cheap and can be 
performed in multiple settings.  The sensitivity and specificity of duplex scan in diagnosing arterial 
stenosis ranges between 70 and 90% in various studies. Additional advantage of arterial duplex is its 
usefulness during an interventional procedure to assess the response [55].  But still angiography 
remains the gold standard.   
 
Major advantages of duplex scan compared to angiography are its non-invasiveness and relatively 
lower cost.  Even though the comparative cost is less than that for an angiography, it still remains 
costly for a patient in the developing/underdeveloped countries.  Hence using this as a screening tool 
for screening in Indian population is out of question as well. 
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Most of the studies which had assessed PAOD used Ankle Brachial Pressure Index (ABPI) as the 
screening tool [56].   This is a simple, relatively cheaper and non-invasive method of screening for 
presence of PAOD.  It can be done using a hand held Doppler machine and requires only a minimal 
training.  This can be performed as an outpatient office test as well.  Due to these advantages, this 
has become the standard screening tool for identifying PAOD in all parts for the world including our 
country.   
 
Ordinary stethoscope was used in the initial days to measure blood pressures for calculation of ABPI.  
But it was found to be less accurate than Doppler measurements. Hence the trend has changed over 
the years to the use of a Doppler machine in determining the blood pressures so as to help in 
calculation of a more accurate ABPI [57] 
 
Patient is made to rest for a period of about 5-10 minutes.  Systolic blood pressures of both the 
brachial arteries are measured with the help of a standard sphygmomanometer and a hand held 
Doppler machine.  Similarly the systolic blood pressures at the ankles are also measured separately 
for each lower limb.  Cuff should be ideally placed about 2.5cm above the ante-cubital fossa in case 
of arm and about 5cm superior to the medial malleolus for the ankle pressures. A clear arterial pulse 
signal should be obtained with the help of the Doppler probe before initiating the test. The cuff is 
then slowly inflated.  The pressures at which the arterial Doppler signals disappear are noted.  The 
cuff is further inflated for another 20 mm Hg.  This has to be maintained for few seconds after which 
slow deflation of cuff is initiated. The blood pressure at which the Doppler signals is re-heard is 
considered as the systolic blood pressure in that vessel/limb [57, 58]. 
 
41 
 
The ankle-brachial pressure index (ABPI) is then calculated by dividing the higher of the two systolic 
blood pressures at the ankle (posterior tibial & dorsalis pedis) by the higher of the two brachial 
systolic blood pressures.   ABPI is thus calculated separately for each leg [57]. 
 
ABPI = Highest systolic blood pressure in one side foot [PTA or DPA]/ Highest systolic blood pressure 
among the brachial artery 
PTA = Posterior tibial artery 
DPA = Dorsalis pedis artery 
 
Diagnosis of peripheral arterial occlusive disease is made when ABPI <0.9 [47, 58].  ABPI below 0.9 
indicates PAOD with 95% sensitivity and 100% specificity for picking up clinically significant occlusive 
disease, in comparison to angiography which is considered the gold standard [59].  Various other 
studies have shown that the sensitivity and specificity of ABPI ranges from 79-95% and 90-100% 
respectively [25, 56].   
 
It is shown that the sensitivity of ABPI can further be increased by adopting a post exercise ABPI 
measurement [22, 25, 60].  During exercise, there is an enhancement in the blood flow to the tissues.  
This excess flow has to happen across a fixed stenotic segment of the vessel, which prevents this 
from happening.  Hence there is a fall in the ankle pressures, which is reflected in the measurement 
of ABPI as well [57]. This is important in identifying mild forms of occlusion which unmasks only 
during an exercise manoeuvre. A post exercise reduction in ankle brachial pressure index to 
abnormal value (<0.9) is considered as significant with respect to occlusion.  Certain studies also 
consider a fall in ABPI to >20-25% as significant for occlusion as well [74]. If the patient develops leg 
symptoms, especially pain during these exercise manoeuvres, it provides further evidence to the 
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vascular origin of symptoms [57]. Various exercise modalities are described in literature.  No 
standard recommendation is available for the same.  Some included tread mill based tests and others 
included simple exercise regimes likes walking in the corridor and heel raise test [22, 60].  The 
adequacy of an exercise regime is also not standardised.  
 
Severity of peripheral arterial occlusive disease can also be defined using ABPI.  An ABPI of <0.4 is 
defined as “critical limb ischemia” especially if associated with tissue loss or rest pain [42].  Critical 
limb ischemia is of significance in the fact that it needs emergent intervention from a trained 
vascular specialist.   
 
  ABPI value can also correlate with the severity of PAOD [42, 25]: 
Normal: 0.91–1.30 
Mild obstruction: 0.70–0.90 
Moderate obstruction: 0.40–0.69 
Severe obstruction: <0.40 
 
It is known that, patients with severely calcified wall of arteries, even a higher systolic blood 
pressure won’t be able to compress the vessel wall.  Hence ABPI will be shown erroneously high [25].   
This cut off has been repeatedly being changed and used in various studies ranging from >1.1 to 
>1.4. Two common examples for the same are chronic kidney disease and long standing diabetes 
mellitus.  Toe arteries are usually compressible even when it’s impossible to compress the pedal 
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arteries.  Hence in these patients with non-compressible pedal arteries, toe pressures or toe-brachial 
index can be obtained instead of ankle brachial index to confirm the diagnosis of peripheral arterial 
disease [25].  
 
Toe pressures are measured by measuring the great toe blood pressure with the help of a digital 
blood pressure cuff and a Doppler probe or a plethysmographic flow sensor. The toe-brachial index 
is calculated by dividing the toe blood pressure by the higher of the two brachial artery pressures 
[57]. TBI of <0.7 and/or toe pressure of <50 mm Hg is taken as abnormal for diagnosis of PAOD [25, 
57].  
 
Vascular specialists could also use segmental pressures, Doppler waveform analysis, pulse volume 
recordings, or ABPI with duplex ultrasonography to document peripheral arterial occlusion and its 
possible anatomic location [25]. 
 
Problems and errors encountered during the ABPI measurement includes: 
- Size of the cuff being not ideal for the patient (small cuff in a fatty or edematous 
leg) leading to wrong values 
- Placement of blood pressure cuff in the wrong place (ideal location being about 
5cm above the medial malleolus) usually leads to erroneously higher ankle 
pressures. 
- Repeated inflation or prolonged inflation of blood pressure cuff leading to an 
erroneously low ankle pressures. 
- Rapid deflation of the blood pressure cuff. 
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- Improper positioning of the patient (erroneously high value can be obtained if the 
ankle pressures are obtained with the leg in a dependent posture) 
- Difficulties encountered in patients with an irregular pulse, leading to erroneous 
values. 
- Effect of central systolic blood pressure : normal range of ABPI could be affected 
by the central systolic blood pressure of the patient at the time of examination 
- Calcified vessels as mentioned earlier 
 
One of the recent meta-analysis showed that low ABPI (marker of PAOD) itself is an independent risk 
factor for cardiovascular mortality alongside the traditional Framingham risk factors [59].  Another 
prospective study of more than thousand random patients aged between 50-74 years re-emphasised 
similar relationship between a low ABPI and risk of future cardiovascular deaths [62].  This study 
found that in patients with evidence of symptomatic PAOD (<0.9 ABPI), the relative risk of 
cardiovascular death was 2.67.  The relative risk in asymptomatic patients was found to be between 
1.74 and 2.08.  There are other multiple studies where in a low ABPI <0.9 has been demonstrated to 
carry high chance of increased cardiovascular mortality and morbidity [25, 63, 64, 65, 66].  
 
There is a good inter-observer reliability in the measurement of ankle brachial index, when done by 
trained persons (κ-value of 0.77-1.0).  
Intra-observer variability in various studies stands between 7.3 to 12% [67].   
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Another important aspect of ABPI value which one needs to keep in mind is a higher than normal 
ABPI value.  Importance given to such a value in the earlier days was very low.  But off late studies 
have repeatedly proved that higher than normal ABPI also is a predictor for an increased all-cause 
cardiovascular mortality in future [68]. 
 
ABPI has emerged as an important screening tool for assessing peripheral arterial occlusive disease 
across the globe.  In countries like ours, where health care affordability is poor, this stands as a 
relatively cheaper tool to assess for the presence of peripheral arterial occlusive disease (PAOD). 
 
The vascular manifestations of HIV are well described in literature. HIV vasculopathy was  
first described as an entity in 1987 [69].  Three clinical syndromes are described with respect 
to HIV and vascular system [70].   
- atherosclerotic occlusive disease 
- non-atherosclerotic disease (vasculites and aneurysms)  
- prothrombotic states  
Among these, atherosclerotic disease is the commonest and vasculitis is the least common 
(about 1%) [71]. 
 
Characteristics of HIV associated vasculopathy differs from general population in the following ways 
[72]:  
- young age of onset 
- less prevalent traditional risk factors 
- more advanced disease at presentation  
- Extensive disease with poor peripheral run off 
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- higher rate of complications especially wound and graft related 
- Increased perioperative and postoperative mortality and morbidity  
 
Surgical outcome has been found to be largely independent of the CD4 values and hence no patient 
should be denied an operation based on low CD4 count [70]. Treatment options have to be 
individualised.  Strict vascular surgical principles should be followed while managing HIV-associated 
occlusive vasculopathy.   
 
Various pathophysiological mechanisms leading to vasculopathy is being studied in HIV 
patients.  Most plausible link is thought to be the endothelial dysfunction [73].  Multiple 
other links described are [70, 74] 
-  immune suppression 
- direct viral injury of endothelium 
- vasculitis  
- worsened metabolic parameters by HAART therapy  
Among these, endothelial injury mediated mechanism stands out as the leading 
pathophysiological mechanism. 
 
Endothelial injury plays a major role in the development of cardiovascular and inflammatory 
pathologies.   This has been described in Human Immunodeficiency Virus (HIV) infection as 
well [75].  It is proved that, various endothelial cells in the body like hepatic sinusoidal cells, 
umbilical venous endothelial cells, marrow stromal endothelial cells or cerebral capillary 
endothelial cells, offer variable permeability for HIV.   Soluble adhesion molecules and 
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procoagulant proteins, which act as markers of endothelial activation, have been found in 
excess in HIV infected patients.   
 
Viral entry into endothelial cells may occur via various mechanisms.  CD4 antigen, 
galactosyl-ceramide receptors and chemokine receptors mediated entry is well described in 
literature.    
 
Cytokines secreted in response to the mononuclear or adventitial cell activation by HIV virus 
or by the action of the secreted HIV-associated proteins (gp 120 and Tat on viral replication) 
can also help in virus penetration of endothelial cells.  Inflammatory cytokines and viral 
proteins can act in synergy leading to endothelial injury.  These dysfunctional or injured 
endothelial cells potentiate inflammation, tissue injury and tissue remodelling, and thereby 
accentuate the development of various cardiovascular diseases including peripheral arterial 
occlusive disease [75].   
 
Other abnormalities predisposing to a procoagulant state have also been detected in HIV 
patients.  This includes antiphospholipid antibodies, lupus anticoagulant, increased von 
Willebrand factor (vWF), deficiency in protein C and S, AT-III (antithrombin) and heparin 
cofactor. Factors such as opportunistic infections and HIV associated neoplasms may also 
contribute to the procoagulant state [76]. 
 
HAART stands for highly active anti-retroviral drugs.  It has formed the centre core of 
treatment for HIV positive patients.   It has helped reduce the morbidity and mortality of 
HIV positive patients.  It decreases the total burden of HIV, maintains good immune system 
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function and helps prevent HIV associated opportunistic infections [77].  In India, these 
drugs are provided free of cost through various ART centres for the needy. 
 
There are different classes of drugs, which are usually combined to treat HIV infection. This 
combination can be termed anti-retroviral therapy (ART), combination anti-retroviral 
therapy or highly active anti-retroviral therapy (HAART).  The decision on which dual NRTI 
combination or ‘backbone’ to use, and which agent to combine it with, is dependent on 
numerous factors, including CD4 count, HIV viral load, drug toxicities and interactions, pill 
burden and viral resistance [77, 78]. Commonly used combinations include 2 nucleoside 
reverse transcriptase inhibitors (NRTI) as a "backbone" along with 1 non- nucleoside reverse 
transcriptase inhibitors (NNRTI), protease inhibitor (PI) or integrase nuclear strand transfer 
inhibitors (INSTI) as a "base" [78].  This combination therapy helps prevent drug resistance 
by suppressing HIV replication.  It does this by reducing the pool of spontaneous resistant 
mutations. Combinations of anti-retroviral agents create multiple obstacles to HIV 
replication and reduce the possibility of a superior mutation.  If a mutation that provides 
resistance to one of the drugs in the combination arises, the other drugs continue to 
prevent the multiplication of that particular mutant [77, 78].  In this way HAART become an 
effective model to treat HIV infection. 
 
ART drugs have various side effects some of which could be serious. Prior to the 
introduction of HAART, it was recognised that HIV infection itself caused dyslipidaemia [79]. 
Declines in total cholesterol, low density lipoprotein cholesterol (LDL-C) and high density 
lipoprotein cholesterol (HDL-C) have been shown in men who seroconverted from HIV-
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negative to HIV-positive [81]. HIV-infected, untreated patients (particularly those with more 
advanced disease) are more likely to have low total, LDL-C and HDL-C and elevated serum 
triglyceride (TGs) than HIV-negative controls [78, 81, 82 ], with lower HDL-C concentrations 
associated with higher viral load and more prolonged duration of infection.  
 
Protease inhibitors are of concern for vascular surgeons and Cardiologists.  Many ART drugs 
have dyslipidaemia properties. Use of protease inhibitors has been associated with 
hypertriglyceridemia and hypercholesterolemia. Ritonavir is a potent inhibitor of the 
cytochrome P450 enzyme system used in the treatment of HIV/AIDS as part of HAART [84]. 
Various trials in healthy volunteers have shown it to have dyslipidaemic properties. 
Triglyceride and LDL-cholesterol levels were shown to increase by 26% and 16% respectively 
after about 2 weeks of treatment [84].  When used in voluntary subjects, in combination 
with other PIs, an enhanced dyslipidaemic property was demonstrated at about 4 weeks 
into the treatment [84, 85]. Effects similar to these were also demonstrated in studies 
comprising of HIV infected patients as well [77]. Dyslipidaemic property varies based on the 
type of protease inhibitors used.  Atazanavir and Darunavir are relatively newer protease 
inhibitors which have been found to have negligible dyslipidaemia properties [77].   
 
Hypertriglyceridemia could be a response to systemic inflammatory reaction in HIV positive 
patients.  IFN-alpha is a marker of systemic inflammation, which is found in excess in HIV 
infected patients. In HIV infected untreated subjects, there exists a good correlation 
between IFN-alpha levels and triglyceride concentrations and triglyceride clearance time 
[77]. 
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Use of protease inhibitors can also be associated with other metabolic derangements in HIV 
patients.  This includes insulin resistance, metabolic syndrome and risk of future cardio 
vascular events including myocardial infarction [56, 86, 87+.  More than just the use, it’s the 
prolonged duration of treatment with these drugs which can cause persisting metabolic 
derangements [56].  Hence it is very important to choose ART regime in a patient with PAOD 
or other cardiovascular morbid illnesses. 
 
Having known all these in general population; peripheral arterial occlusive disease is a least studied    
entity in HIV patients.  There are only limited studies which had assessed the prevalence of same in 
this group especially from India.  Studies have found various risk factors (few different from the 
traditional risk factors) which independently contributed to the occurrence of PAOD in HIV patients 
[56]. 
 
Prevalence of PAOD in HIV patients using ABPI as the screening tool in limited studies varied 
from 0.9% to 22.4% [56].   
 
The Swiss HIV cohort study [74] recruited 92 consecutive HIV positive patients. Claudication 
was reported by 15.2% of the patients. All patients were assessed for presence of PAOD 
using ABPI as the tool.  PAOD was found in 20.7% of the patients. Among these, 9.8% had an 
abnormal ABPI (<0.90) at rest, and 10.9% had significant post exercise reduction in ABPI to 
>25%.  84.2% of those with PAOD were investigated further with arterial duplex scan, all of 
whom had atherosclerotic occlusions of the lower limb arteries.   
Age, diabetes, smoking, and low CD4 counts (<200) were identified as independent 
predictors of PAOD in this population. 
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The study concluded that the prevalence of symptomatic and asymptomatic PAOD is high 
among HIV population compared to general population.  This study was important in the fact 
that; it used post exercise ABPI also, which helped them diagnose patients with mild forms of 
occlusion.  
 
Another study by Palacios et al [88] recruited HIV positive subjects for assessment of PAOD 
with a control group.  82.8% patients were males and 17.2% were females. ABPI was used as 
the screening tool in this study too.  
The prevalence of PAOD was found to be significantly greater among the HIV positive 
patients in comparison to HIV negative patients (10.2% vs 1%).  HIV-group in comparison to 
controls comprised of - more smokers (30.3% vs 46.5%), those with higher BMI (24.8 kg/m2 vs 
27.7 kg/m2), DM (31.3% vs 12.2%),  higher proportion of dyslipidaemia (69.4% vs 36.7%), and 
higher cardiovascular risk (29.5% vs 13.4%) as calculated by Framingham's criteria. 
 
Study by Olalla et al [56, 89] recruited 147 HIV positive patients and found a PAOD 
prevalence of 22.4% using ABPI as the screening tool.  This study also proved a positive 
association between PAOD and use of protease inhibitors (OR 2.7) and also higher chance of 
dyslipidaemia in HIV patients treated with PI (OR 2.68).   
Another important finding was the strong association of low CD4 cells with an abnormal 
ABPI. 
 
Study by Gutierrez et al [90] studied the association between an abnormal ABPI and carotid 
artery intima-media thickness (IMT). An increased carotid intima media thickness was found 
to be associated with low ABPI (<0.9). Further statistical analysis demonstrated significant 
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differences between numbers of traditional cardiovascular risk factors in patients with low 
ABPI, compared to others.  This study too showed significant association of low ABPI to low 
CD4+T lymphocyte count.  
 
 
Study by Sharma et al [91] studied the prevalence of PAOD in HIV positive women (average 
age 39.6 years) and HIV negative women (average age 36.4 years). Low ABPI was found only 
in 0.9% (among the two groups of patients). Prevalence of increased ABPI was similar (7.2% 
vs 6.3%) among these two groups. On multivariate analysis, increased ABPI was found to be 
associated with smoking (OR: 2.53; 95% CI, 0.99–6.43), BMI <18.5 (OR: 11; 95% CI, 1.61–
75.63) and overweight status (OR 5.4; 95% CI, 1.13–25.89). HIV positive women were also 
found to have a higher proportion dyslipidaemia (HDL-C ≤35 mg/dl: 26.2% vs 5.2% and TG 
≥200 mg/dl: 13.4% vs 5.2%). 
 
Many studies in literature used only rest ABPI with no post-exercise modifications to 
identify the dormant disease.  And moreover, the prevalence of ABPI >/= 1.3 was also high 
in many studies.  This may probably be under estimating the magnitude of problem since an 
ABPI above 1.3 does not rule out arterial occlusion.  It just means that, the “vessels are non-
compressible/calcific”.  Those studies did not probe more into the details of ABPI >/= 1.3 
with other screening tools (TBI or toe pressures). 
 
Study by Van Marie etal [72] demonstrated the outcomes of HIV positive patients who were 
treated in a specialised vascular centre. 154 consecutive HIV positive patients attending the 
specialised vascular clinic of the hospital were recruited. About 59% of these patients 
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presented with vascular occlusive disease. Majority of patients were males (71 Vs 20).  
Mean age at presentation was 44.2 years. More than 90% of the patients presented with 
late stage disease (Fontaine III/IV).  Percentage of patients who presented with evidence of 
lower limb ischemia, upper limb ischemia and symptomatic carotid artery stenosis were 
56.4%, 0.01% and 0.01% respectively. Traditional risk factors for PAOD were present, but 
the incidence was less than that in the classic atherosclerosis population.  
Perioperative mortality rate was 6.95% and rate of primary amputation was 31.91%.  
Secondary amputation rate was high with a poor limb salvage rate (36.1%) after femoro-
popliteal bypass (considered as marker of outcome in vascular surgery as part of infra-
inguinal bypass). This created more duration of hospital stay and financial burden on the 
patient in addition to adding a disability.  
Operated patients had a relatively higher long term mortality rate approaching 20% over a 
mean follow-up time of 15.4 months. Poor nutritional status as assessed by albumin was 
found to be an important predictor of surgical outcome. 
 
Prevalence rate of PAOD in general population is estimated to be 1% at 50 years and 3% at 60 years 
of age [19].  Taking into consideration this, the high prevalence obtained in the above limited studies 
is alarming.  It also point to the fact that there could be additional risk factors which play a role in the 
causation of PAOD in HIV population like a low CD4 cell count. 
 
Interestingly there are very few studies on this topic from Indian subcontinent where HIV and its 
associated diseases are an alarming problem.   Most of the studies conducted in the west were on 
particular subset of patients:    
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The Swiss HIV cohort study [74] recruited HIV patients above 40 years (prevalence – 21%) and 
another study recruited pregnant HIV positive women less than 40 years (prevalence – 0.9%) [91]. 
Most of these studies were limited by their small sample size.  There is no large scale studies 
conducted in this population taking into account all adult patients, especially from India.  
 
My study aims to bring out the prevalence of this condition in HIV positive patients using cost 
effective, relatively sensitive tests (ABPI & post exercise ABPI+/- TBI & Toe pressure).  It also aimed at 
assessing risk factors possibly causative in this population in Indian setting, especially looking into the 
details of ART use and years of therapy.   
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Design  
A prospective cross sectional study was designed including all adult HIV positive patients (>/= 18 
years) during the study period 
 
Duration of study 
The study was conducted from December 2012 to September 2014.   
Recruitment was completed by September 2014. 
 
Inclusion and exclusion criteria 
 
Inclusion criteria: 
All adult HIV positive patients (>/=18 years) presenting to the outpatient or inpatient clinics 
of Christian Medical College and Hospital including the ART clinic 
 
Exclusion Criteria:   
All non-consenting patients  
Critically ill (who cannot perform post-exercise ABPI) 
 
 
 
 
57 
 
 
Sample size:  Sample size calculated was 400 
 
There were limited studies in literature addressing the same research question.  From those 
limited studies available in literature, the prevalence varied from 0.9% to 20.7%.   
The study conducted by the Swiss group which took both rest and post exercise ankle 
brachial pressure index into consideration found a prevalence of 20.7%.   
In Indian setting as well, we expected the prevalence of peripheral arterial occlusive disease 
to be similar. Hence it was decided to keep the expected prevalence (p) as 20%.   
Precision (d) was kept at 4% to allow for a deviation of 4% on either side. 
 
Sample size was calculated using the formula 4pq/d2 
 
Sample size = 4pq/d2  
                   = 4 x 20 x 80/4x4 
                   = 400 
P = 20  
q = (1-p) 
d = 4 
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FOR IDENTIFYING POSSIBLE RISK FACTORS  
The same patients were utilized for the identification of risk factors. As we were going to 
have a reasonably large sample size of 400, and the number of expected outcome of 
peripheral arterial occlusive disease would be around one-fifth, risk factor analysis was done 
comfortably using multivariable logistic regression analysis.  
 
Recruitment:  
IRB approval 
Institutional Research Board (IRB) approval was obtained for the proposed study.  
 
Settings 
Adult HIV positive patients attending the outpatient and inpatient clinics of Christian 
Medical College and Hospital were recruited into the study. 
Most of the patients were recruited from the ART (Anti-Retroviral Therapy) clinic attached 
to the Department of Infectious Disease Training and Research Centre (IDTRC).  ART clinic 
was attended by about 20-30 patients per day.   There are about 10 new HIV patients seen 
in this clinic per week. This made recruitment easy as all the patients who were attending 
this clinic were HIV positive patients, and there was hardly any need to look around for HIV 
patients from other clinics.  And more over, most of these patients were being referred from 
other clinical departments of the hospital as well.   
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Information leaflet 
Patients were provided verbal and written (annexure: 1) information about the study.  All 
details pertaining to the study was included in the patient information leaflet.  And the 
leaflet was made in simple language understandable to the layman.  This was prepared in 
four languages (English, Hindi, Tamil and Telugu) since our hospital catered to people from 
different parts of the country.   Since my study did not involve any invasive procedure, all 
patients whom I interviewed were willing for the study.  Probably for the same reason, they 
were hardly interested in reading through the entire leaflet before consenting for the study! 
 
Consenting 
A written informed consent (annexure:2) was obtained from all the consenting patients.  
Consent forms were also made in all four languages described above.  Consent form 
included all the details pertaining to an ideal consent form.   
 
Data collection 
Data was collected using a preformed proforma (annexure:3).   
The proforma was divided into many parts.   
First part included demographic details of the patient.  It also included hospital number of 
the patient and a study code no against all these hospital numbers so as to conceal the 
identity of the patient.  Patients were explained that their identity will be concealed.  And 
this was of greater concern for most of the patients whom I recruited owing to the nature 
and stigma of the disease they are living with.   
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Second part included the Edinburgh Claudication Questionnaire (as described elsewhere).   
 
This questionnaire was used initially to categorize consented patients into – Symptomatic 
and asymptomatic.  Only those patients who give “YES” to all questions in the questionnaire 
will be considered as having true claudication.  
 
Irrespective of being having true claudication, all patients will undergo ABPI with toe 
pressures since it is shown in the Swiss study and others that prevalence of asymptomatic 
peripheral arterial occlusive disease is higher in this particular group (HIV patients). These 
cases are the ones whom I was expecting to pick up by the post-exercise regime. 
 
Third part included traditional risk factor assessment.   
 
Fourth part includes the treatment (HAART) details.   
 
Treatment information was obtained from the ART notebook maintained by all these 
patients.   
 
Information with respect to the date of diagnosis, enrolment for ART, drug regime, recent 
CD4 count, reason for drug change were all could be obtained from this books alone. 
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Fifth part included the clinical examination including palpation of all peripheral pulses and 
appropriate documentation.   
 
Sixth part includes the entry of available lab parameters of significance to my study.  
 
Last part included the measurement of ABPI and Toe pressure and its documentation.  
 
Dyslipidaemia was diagnosed based on a history of dyslipidaemia, history of lipid lowering 
drug intake, or defined based on Third Report of the National Cholesterol Education 
Program (NCEP) as triglyceride >/= 150, LDL cholesterol >/= 130, total cholesterol >/= 200 or 
HDL cholesterol <40 mg/dL[92] 
 
Hypertension was diagnosed based on history of HTN, history of antihypertensive intake or 
as defined by the JNC7 guidelines: In people aged 18 years or older hypertension is defined 
as a systolic and/or a diastolic blood pressure measurement consistently higher than an 
accepted normal value (currently 139 mmHg systolic, 89 mmHg diastolic) [93] 
 
Diabetes mellitus was diagnosed based on a history of known DM, history of anti-diabetic 
medications, or WHO criteria by demonstrating any one of the following: fasting plasma 
glucose level >/= 126 mg/dl and/or 2 hours post prandial plasma glucose >/= 200 mg/dL [94] 
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The collected data was compiled and was analysed for distribution of disease at the end of  
 
study. Risk factor were documented as “present” if the answer to the following questions  
 
were given as “YES”. A “NO” response will be marked as “absent” risk factor. 
 
 
- Do you smoke / ever smoked? How often? 
 
- Do you use tobacco in any other form? How often? 
 
- Do you drink alcohol on a regular basis? How often? 
 
- Do you have a past history of vascular events?  
 
- Do you have a family history of any of the above events? 
 
- Are you a diagnosed case of DM? History of anti-diabetic medications? 
 
- Are you a diagnosed case of HTN? History of anti hypertensives? 
 
- Are you a diagnosed case of dyslipidaemia? History of lipid lowering agent 
intake? 
 
All patients who were found to have evidence of peripheral arterial occlusive disease were 
informed regarding the same.   
All patients were explained regarding the need for further evaluations and treatment.  
They were explained regarding the limitation of my study in providing further evaluations 
and treatment.   
 All patients were referred to the Department of Vascular Surgery unit of our hospital for 
further evaluations and management if necessary.  But majority of them had not turned up 
to the clinic so far. 
Health education with respect to the peripheral arterial occlusive disease and life style and 
risk factor modifications were explained to them.   
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A total of 403 such patients were recruited wherein the calculated sample size was 400. 
Originally planned for 400, at the end of final data entry it was found that 403 patients were 
recruited.  But owing to the benefits of adding on those patients and also to avoid bias, they 
were not excluded.  These three patients were included for the final analysis as well. 
 
All patients had to be recruited by myself and all patients required ABPI to be measured by 
me.  This was made a compulsory in the study design so as to avoid the inter observer 
variability.  For the same reason, it was not possible to recruit all consecutive patients due 
to the time constraints of a post graduate student. 
 
Measurement of ABPI and Toe pressure 
 
Ankle brachial pressure index was measured using a hand held Doppler machine and 
standard blood pressure cuff attached to a sphygmomanometer.   
All patients were required to rest in supine position for 5 minutes 
Rest ABPI was measured in the standard way as described in literature.   
All patients made to walk for 10 minutes under supervision 
Post exercise ABPI was measured in a similar manner.   
Bilateral ABPI was calculated and entered in the proforma.   
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All patients whose ABPI was >1.1 (after rounding off) were sent to the Vascular lab attached 
to the Department of Vascular Surgery of our hospital for bilateral toe pressure 
measurement.   
Toe pressures were measured in the standard way and entered in the proforma. 
 
The diagnosis of peripheral arterial occlusive disease (primary outcome) was based on the    
AHA (American Heart Association) guidelines (25):  
 
Any ABPI (Ankle Brachial Pressure Index) <0.90 will be taken as significant.  
 
In those patients where there is evidence of calcific, non-compressible vessels (Ankle 
brachial pressure index >1.1 (like chronic kidney disease and diabetes mellitus), following 
guidelines were used for diagnosis of PAOD. 
- Toe pressures (TP) <50 mm Hg and/or  
- Toe brachial index (TBI) < 0.7  
 
These are the standard cut off used worldwide and even in our institution.  
 
A post exercise reduction in the ABPI value was considered significant if; 
                    -    The value fall to abnormal, i.e <0.9 and/or  
                    -    >25% reduction from the baseline value  
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Above figure shows the basic instruments needed for measurement of ankle brachial index 
which includes: 
- Hand held Doppler machine 
- Blood pressure cuff with sphygmomanometer  
- Lubricant jelly. 
 
These instruments can be portable and hence the measurement of ABPI becomes easy in all 
settings.  
66 
 
 
This picture shows ankle pressure being measured in the right posterior tibial artery.  Note 
the supine position of the patient and the place at which the blood pressure cuff is tied. 
 
This picture shows ankle pressure being measured at the left dorsalis pedis artery. Again 
note the position of patient and position of blood pressure cuff. 
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Toe pressure cuff being attached to the right big toe for measurement 
  
Toe pressure being measured in the right big toe.  Note the wave form in the screen which 
depicts presence of active blood flow 
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Data entry 
Information from the proforma was entered in Microsoft excel sheet for future analysis and 
interpretation.  This excel sheet with the hospital numbers were made available only to the 
primary investigator, co-investigators and the guides.   Other persons who had helped in the 
preparation of final paper were given only the study code numbers.  
 
Maintenance of data and confidentiality preservation 
HIV positive status of the patient was kept confidential. All study related records were in 
 
 the sole custody of the Principal Investigator. Completed consent forms and questionnaires  
 
were locked in cupboards. All digital data were stored in password-protected computer file.  
 
 
To further protect the identity of the participants, each person participating in  
 
Each patient was assigned a study code number at the top of their consent form, which  
 
was used whenever possible instead of that person’s personal identity details. This code  
 
number was used for communications with a third party excluding the guide and co- 
 
investigators. This way the third parties were unaware of the patient details. 
 
Outcomes measured 
Primary Outcome: 
To measure the prevalence of peripheral arterial occlusive disease (PAOD) in adult HIV 
positive (>/=18 years)  
 Secondary Outcome/s: 
Identification of risk factors in the causation of PAOD in this population 
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Statistical Analyses 
 
- Data entry was done using Microsoft Excel.  
- Descriptive analysis of the study population was done.  
- Prevalence/frequency distribution of disease in each subset group (Eg: Diabetics, tobacco users, 
CD4 <300 HIV patients) was calculated separately.  
- Risk factors and lab parameters under study were initially examined using a univariate analysis 
with chi-square test.   
- Selection of risk factors was based on both clinical and/or statistical usefulness.   
- Multivariate logistic regression analysis was performed to identify independent factors that are 
associated with risk of developing PAOD in this population.  
- All analysis was done using SPSS statistical software. 
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A total of 403 patients were recruited into the study over the proposed time period.   
 
1. Demography – results 
 
Sex 
 
 
Out of 403, 238 patients (59.1%) were males and 165 (40.9%) were females.  
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Age (years) 
 
 
- Average age of the study population was 41.45 years.  
- Majority of patients were in 30-50 age groups as depicted in the histogram. 
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2. Symptomatology – results 
 
Claudication 
 
 
 
 
19 patients (5%) reported claudication as per the Edinburgh Claudication Questionnaire.  
 
 
 
74 
 
Mean claudication distance (Kilometres) 
 
 
 
- Mean claudication distance by the claudicants was 1.03 kilometres. 
- No patient reported rest pain or features of tissue loss (ulcers or gangrene) especially 
among the claudicants.    
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3. Traditional risk factors- results 
 
Tobacco 
 
 
 
- 79 (19.6%) patients used tobacco in some form. 
- Predominant form of tobacco use was smoking. 
 
 
 
76 
 
Alcohol  
 
(History of this was obtained as to see for any relation in this particular population with 
causation of PAOD – it is not a traditional risk factor) 
 
 
 
- Alcohol was used by 58 (14.4%) patients. 
- 57 were males and 1 was female. 
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Diabetes mellitus 
 
 
 
32 patients (7.9%) were diabetic and 371 (92.1%) were non-diabetic. 
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Hypertension 
 
 
 
- 63 patients (15.63%) were hypertensive and 340 patients (84.37%) were not 
diagnosed with hypertension. 
- Majority of the hypertensive patients in this population was irregular on 
treatment. 
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Dyslipidaemia 
 
 
 
- 18 patients (4.5%) were diagnosed with dyslipidaemia and 385 patients (95.5%) were 
not diagnosed with dyslipidaemia. 
- Majority of patients who were diagnosed with dyslipidaemia were on life style 
modifications rather than medications. 
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Ischemic heart disease/Acute coronary syndrome/ angina/coronary artery disease 
(IHD/ACS/CAD) 
 
 
 
3 patients (0.7%) had prior history suggestive of ischemic heart disease/acute coronary 
syndrome/coronary artery disease/history suggestive of coronary angina. 
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Cerebrovascular accidents/transient ischemic attacks (CVA/TIA) 
 
 
 
1 patient (0.2%) had history of prior stroke from which the patient had recovered 
completely. 
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Family history of vascular events/vascular disease  
 
 
 
9 patients (2.2%) had history suggestive of some vascular disease in the family. 
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3. Treatment details – Results 
 
ART patients  
 
 
 
- Among 403 patients, 381 patients (95%) were currently on ART and 22 (5%) were 
not yet initiated on ART. 
- These patients who were on ART, all were regular on treatment currently.   
- Among those who were not on ART, the immune status as assessed by CD4 count 
was good. 
84 
 
 
Duration of HIV (months) 
 
 
Mean duration since HIV was diagnosed was 59.35 months 
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Drug regime 
Most of the patients were on ZLN (Zidovudine, Lamivudine and Nevirapine) combination 
therapy.   
But recently there was a change on the regime to TLN (Tenofovir, Lamivudine and 
Nevirapine) or TLE (Tenofovir, Lamivudine and Efavirenz) owing to a higher incidence of 
Zidovudine induced anemia. 
 
Use of protease inhibitors (PIs) 
 
 
Among the 381 patients who were on ART: 
- 122 patients were on one of the protease inhibitors at least or had history of 
using one of the protease inhibitors in the past. 
- 259 patients never had history of protease inhibitor use.  
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Duration of protease inhibitor (PIs) use (months) 
 
 
- Mean duration of protease inhibitor use was 16.57 months. 
- Majority of patients had history of using protease inhibitors for less than 30 
months. 
This could explain the recent trend of changing to a drug regime based on one of the 
protease inhibitor. 
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4. Body mass index (BMI) 
 
 
 
Among 403 patients, majority of patients fell into the normal category and there was almost 
equal percentage of patients who were overweight or underweight. 
 
This also point towards a better nutritional status of these patients in spite of being having 
an immune suppressive disease. 
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5. CD4 count 
 
 
 
- Mean CD4 count was 456.04. 
- This reflected a good immune system in majority of patients, probably related to 
regular HAART therapy with suppressed viral load. 
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6. Haemoglobin (gm %) and Albumin (gm%) levels 
 
 
- Mean haemoglobin was 12.52 gm%. 
- Mean albumin was 3.97 gm%. 
 
These two factors again reflected the good nutritional status of this group of patients in 
spite of having acquired an immunosuppressive infection. 
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Prevalence of peripheral arterial occlusive disease (PAOD) 
 
 
 
- Among 403 patients, peripheral arterial occlusive disease (PAOD) was identified in 
31 patients using ABPI +/- toe pressures as the screening tool.   
- Hence the prevalence of peripheral arterial occlusive disease in this study was 
found to be 7.69%. 
- Among the PAOD group, 17 (54.8%) were females and 14 (45.2%) were males. 
- Among the PAOD group, 3 patients were found to have >25% reduction in post-
exercise ABPI which was considered significant.  But all these patients also had 
abnormal ABPI at rest or post exercise. 
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Results of bivariate analysis 
Age and PAOD 
Variable PAOD- YES PAOD- NO  p value 
Age  40.71 ± 8.46 41.51 ± 8.25 0.603 
 
Conclusion – In bivariate analysis, age did not play a significant role in the prediction of 
PAOD. 
 
Sex and PAOD (peripheral arterial occlusive disease) 
Variable PAOD - YES PAOD  - NO p value 
Male 14 (45%) 224 (60%) 0.128 
Female 17 (55%) 148 (40%) 
 
Conclusion - In bivariate analysis, sex had no statistically significant association with 
development of peripheral arterial occlusive disease in HIV patients. 
 
Body mass index (BMI) and PAOD 
Variable PAOD – YES PAOD – NO p value 
BMI 21.59 ± 5.187 22.20 ± 3.99 0.429 
 
Conclusion – BMI had no significance with respect to the prediction of PAOD in HIV patients. 
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Tobacco and PAOD 
Variable PAOD - YES PAOD - NO p value 
Tobacco – YES 4 75 0.364 
Tobacco – NO 27 297 
 
Conclusion - In bivariate analysis, tobacco had no statistically significant association with 
peripheral arterial occlusive disease in HIV patients. 
 
Alcohol and PAOD 
Variable PAOD - YES PAOD - NO p value 
Alcohol – YES 3 (10%) 55 (15%) 0.597 
Alcohol - NO 28 (90%) 317 (85%) 
 
Conclusion - In bivariate analysis, alcohol had no statistically significant association with 
peripheral arterial occlusive disease in HIV patients. 
 
Diabetes mellitus (DM) and PAOD 
Variable PAOD - YES PAOD - NO p value 
DM – YES 1 (10%) 31 (15%) 0.494 
DM – NO 30 (90%) 341 (85%) 
 
Conclusion- In bivariate analysis, diabetes mellitus had no statistically significant   
association with peripheral arterial occlusive disease in HIV patients. 
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Hypertension (HTN) and PAOD 
Variable PAOD - YES PAOD - NO p value 
HTN – YES 5 (16%) 
 
58 (16%) 
 
 
1.000 
 
 
HTN - NO 26 (84%) 313 (84%) 
 
Conclusion - In bivariate analysis, hypertension had no statistically significant association 
with peripheral arterial occlusive disease in HIV patients. 
 
Blood pressure (BP) and PAOD 
Variable PAOD- YES PAOD- NO p value 
BP (mm Hg) 124.39 ± 17.71 126.40 ± 18.25 0.554 
 
Conclusion – Total cholesterol, HDL cholesterol, LDL cholesterol, Triglycerides and Blood 
pressure were found to be no significant predictor of abnormal ABPI (PAOD). 
 
History of dyslipidaemia and PAOD 
Variable PAOD - YES PAOD - NO p value 
Dyslipidaemia – YES 1 (3%) 
 
17 (5%) 
 
 
1.000 
 
 
Dyslipidaemia - NO 30 (97%) 355 (95%) 
 
Conclusion - In bivariate analysis, history of dyslipidaemia had no statistically significant 
association with peripheral arterial occlusive disease in HIV patients. 
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Total cholesterol and PAOD 
 
Variable PAOD – YES PAOD – NO p value 
Total Cholesterol 180.88 ± 38.63 164.82 ± 3.99 0.333 
 
HDL cholesterol and PAOD 
 
Variable PAOD – YES PAOD – NO p value 
HDL Cholesterol 39 ± 12.67 37.16 ± 12.34 0.686 
 
LDL cholesterol and PAOD 
 
Variable PAOD – YES PAOD – NO p value 
LDL Cholesterol 104.75 ± 27.71 96.27 ± 28.86 0.424 
 
 
Conclusion: In bivariate analysis, total cholesterol, LDL cholesterol, HDL cholesterol had no 
statistically significant association with peripheral arterial occlusive disease in HIV patients. 
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Ischemic heart disease (IHD)/acute coronary syndrome (ACS)/ angina/coronary artery 
disease (CAD) and PAOD 
 
Variable PAOD - YES PAOD - NO p value 
IHD/ACS/CAD – YES 0  
 
3 (1%) 
 
 
1.000 
 
 
IHD/ACS/CAD - NO 31 (100%) 369 (99%) 
 
Conclusion - In bivariate analysis, presence of ischemic heart disease/acute coronary 
syndrome/ angina/coronary artery disease had no statistically significant association with 
peripheral arterial occlusive disease in HIV patients 
 
Cerebrovascular accidents (CVA)/Transient ischemic attacks (TIAs) and PAOD 
 
Variable PAOD – YES PAOD- NO p value 
CVA/TIA – YES 0  
 
1 (1%) 
 
 
1.000 
 
 
CVA/TIA - NO  31 (100%) 371 (99%) 
 
Conclusion - In bivariate analysis, history of cerebrovascular accident (CVA) or transient 
ischemic attacks (TIAs) had no statistically significant association with peripheral arterial 
occlusive disease in HIV patients 
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Family history of vascular events/disease and PAOD 
Variable PAOD – YES PAOD – NO p value 
F/H/O vascular 
events – YES 
1 (3%) 
 
8 (2%) 
 
 
0.517 
 
 
F/H/O vascular 
events - NO 
30 (97%) 364 (98%) 
 
Conclusion – In bivariate analysis, family history of vascular events (like myocardial 
infarction, stroke) or vascular disease had no statistically significant association with 
peripheral arterial occlusive disease in HIV patients 
 
Duration of HIV and PAOD 
Variable PAOD – YES PAOD – NO p value 
Duration of HIV 
(months) 
33.65 ± 61.50 35.08 ± 52.33 0.001 
 
Conclusion – Duration of HIV was significantly associated with prediction of PAOD  
 
Duration of HIV treatment (HAART) and PAOD 
Variable PAOD – YES PAOD – NO  p value 
Duration of HAART 29.11 ± 36.11 47.05 ± 37.23 0.001 
 
Conclusion – Duration of treatment (HAART) was found to be a significant predictor of 
PAOD  
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Use of protease inhibitors (PIs) and PAOD 
Variable PAOD - YES PAOD - NO p value 
PIs – YES 17 (57%) 
 
105 (30%) 
 
 
0.004 
 
 
PIs – NO 13 (43%) 246 (70%) 
 
Conclusion – In bivariate analysis, use of protease inhibitors had statistically significant 
association (p value = 0.004) with peripheral arterial occlusive disease in HIV patients 
 
Duration of treatment with protease inhibitors (PIs) PAOD 
Variable PAOD – YES PAOD – NO p value 
Duration of PIs 9.57 ± 9.84 17.70 ± 17.50 0.018 
 
Conclusion – Duration of treatment with protease inhibitors was found to be an important 
predictor of PAOD in HIV patient population 
 
CD4 count and PAOD 
Variable PAOD – YES PAOD – NO p value 
CD4 < 300 15 (48%) 
 
109 (29%) 
 
 
0.041 
 
 
CD4 > 300 16 (52%) 263 (71%) 
 
Conclusion – In bivariate analysis, CD4<300 was had statistically significant association (p 
value = 0.041) with peripheral arterial occlusive disease in HIV patients 
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Multivariate analysis 
Based on the bivariate analysis of continuous as well as non-continuous variables, duration 
of HIV, treatment duration, use of protease inhibitors, CD4 count <300 were chosen for 
multivariate analysis. 
 
Variables Odds Ratio 95% C.I P value 
Treatment Duration 1.002 0.98, 1.03 0.889 
HIV Duration 0.984 0.96, 1.08 0.189 
CD4 count 
< 300 
>300 
 
1.93 
1 
 
0.88, 4.23 
 
0.101 
PI 
Yes 
No 
 
2.64 
1 
 
1.22, 5.74 
 
0.014 
 
In the multivariate analysis, following results were obtained: 
 
1. Use of protease inhibitors (OR-2.64), low CD4 count <300 (OR-1.93) and prolonged 
duration of ART treatment (OR-1.002) were found to be associated with a higher risk of 
developing peripheral arterial occlusive disease in HIV positive population.   
 
2. Among those, the only risk factor which attained statistical significance for causation of 
peripheral arterial occlusive disease was protease inhibitor use (p = 0.014). 
 
3. In those with protease inhibitor use, duration of treatment with this agent was also found 
to be significantly associated (p = 0.018) with peripheral arterial occlusive disease 
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Peripheral arterial occlusive disease is a well-known entity in all parts of the world.  There 
are multiple risk factors which are described in literature to be associated with causation of 
this disease in general population.  This includes smoking, diabetes mellitus, hypertension, 
prior history of cardiovascular events and family history of vascular disease/events.   
 
It has been repeatedly proven that peripheral arterial occlusive disease is a marker of future 
cardiovascular events like stroke and myocardial infarction.  Hence the recognition of this 
disease in the early stage is important with respect to the early initiation of therapy and also 
in helping to prevent the other cardiovascular morbidities. 
 
Human immunodeficiency virus (HIV) causes AIDS.  There are multiple presentations of this 
disease including opportunistic infections. HIV associated vasculopathy is well described in 
literature and most common aetiology for the same is atherosclerosis.  
 
Prevalence of peripheral arterial occlusive disease in general population has been 
repeatedly studied.  But there are only very few studies which had tried to identify the 
prevalence of this problem in HIV positive patients. This could probably be due to the under-
recognition of this disease in this population.  There is hardly any study from India where 
HIV is a growing problem of concern.  
 
The morbidity and mortality associated with peripheral arterial occlusive disease in HIV 
population could be higher than that in the general population owing to the depressed 
immune system. 
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This study was designed as an attempt to address the above problem in an Indian setting.  
Peripheral arterial occlusive disease in HIV positive patients were studies using widely 
accepted definitions and standardised screening tools.  
 
Symptomatology was assessed with the help of Edinburgh Claudication Questionnaire.  
Intermittent claudication was reported by 4.7% of study population.  Among those with 
PAOD (n=31), 16.1% of patients reported PAOD.  This was found to be statistically significant 
proving the strong association between “intermittent claudication” and presence of 
peripheral arterial occlusive disease in this population (p value - 0.011).  This has been 
repeatedly proven in studies conducted in general population as well as in HIV population.  
 
Another important point to be noted here is the fact that 83.9% patients with PAOD and HIV 
did not report intermittent claudication.  These patients form the asymptomatic group.  This 
point also has been repeatedly proved in studies that a major proportion of HIV positive 
patients with PAOD are asymptomatic.  Hence it is very important to screen all HIV patients 
for PAOD, especially to pick up these asymptomatic ones.  They can be managed largely 
with life style modifications, exercises or a change in drug regime. 
 
Ankle brachial pressure index (ABPI) was used as the main screening tool to identify 
peripheral arterial occlusive disease. Patients who had high ABPI (suggesting non-
compressible vessels) also required measurement of toe pressures to rule out PAOD.  
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Measurement of ABPI and toe pressures was according to standard protocols in the vascular 
laboratory attached to the Department of Vascular Surgery.  Measurement of ABPI by a 
single investigator using same Doppler machine and blood pressure cuff helped eliminated 
inter-observer variability and probably helped reduce the intra-observer variability as well.   
 
Study population involved patients from almost all age groups >18 years and the mean age 
was around 40. Among those with PAOD, the mean age was 40.71.  This proves that the 
study involved significant number of patients on either side of this age which is a good 
representation of adult HIV positive patients. 
 
Study involved about 41% female patients and 59% males.  This showed a good 
representation of both sexes in the study.  Hence the results of the study could be 
generalised as well. 
 
Prevalence of peripheral arterial occlusive disease obtained in this study was about 7.69%.  
And this in comparison to other similar studies (mentioned above )again proved that the 
prevalence of this disease in this population could be more than what is thought.  And more 
over this could probably be the only large scale study from India which addressed the 
problem in this particular population.  Prevalence of PAOD in general population was found 
to be about 1% at 50 years and about 3% at 60 years. Considering this data, the high 
prevalence obtained in this study could be alarming.  This means that these patients are at 
high risk of other cardiovascular morbidities in the future as well in comparison to general 
population. Hence a comprehensive system needs to be formulated to address this issue in 
this population.   
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Post exercise modification of ABPI had helped many researchers in identifying 
milder/dormant forms of occlusion.  My study also assessed ABPI with a post exercise 
modification as mentioned earlier.  This definitely had helped in identifying more cases of 
PAOD.  Utilisation of this modality has been repeatedly proven to be of help in identifying 
more asymptomatic patients.  Many studies which utilised this modification have found a 
higher prevalence of peripheral arterial occlusive disease in HIV patients, in comparison to 
studies which have not utilised the same.  
 
Traditional risk factors associated with peripheral arterial occlusive disease includes: 
Diabetes mellitus, smoking, hypertension, obesity, metabolic syndrome, prior cardiovascular 
disease, family history of vascular disease/cardiovascular events.   
 
It has been shown in many studies that these traditional risk factors are not prevalent in HIV 
positive PAOD patients. This study also found a similar result. None of the traditional risk 
factors were found to be significant in the univariate or multivariate analysis for the 
causation of PAOD in this population.  This could mean that the patient selection for 
screening should not include only those with traditional risk factors.  In fact it is prudent to 
include all HIV positive patients irrespective of the presence or absence of traditional risk 
factors.  
 
So it could be proposed that all HIV patients need to be screened for presence of peripheral 
arterial occlusive disease since the prevalence is high and also the prevention as well as 
treatment could be initiated at the earliest.  
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Another important link to the development of PAOD in HIV patients is the use of HAART.  
After the introduction of HAART (Highly Active Anti-Retroviral Therapy), the morbidity and 
mortality of HIV and associated opportunistic infections has significantly reduced.  Many 
studies have repeatedly proved the development of various metabolic abnormalities 
secondary to HAART therapy.  This included metabolic syndrome, insulin resistance, and 
dyslipidaemia. And as we all know, all these factors have been well described in literature to 
be the aetiological agents for any cardiovascular disease including peripheral arterial 
occlusive disease.  
 
This study also was aimed at finding any similar association.  Among all class of ART agents, 
use of protease inhibitors was found to be associated with PAOD.  These drugs in 
comparison to other ART drugs cause significant metabolic derangements. Our final analysis 
has showed that there is statistically significant association (p value- 0.011) between use of 
protease inhibitors and development of PAOD.  
 
Most of our patients who were receiving protease inhibitors were using “tenofovir”. 
Whether other protease inhibitors also have a similar association need to be proved in large 
scale epidemiological studies.   
 
Certain studies also had proved that the duration of treatment with protease inhibitors also 
is equally important in the causation of PAOD.  Average duration of treatment with protease 
inhibitors in our study was 16.57 months.   
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Many of these patients who were on this drug had never had their lipid profile being 
checked.  This study helped us initiate lipid profile screening for all these patients.   
 
The higher prevalence of PAOD in this population could be due to many reasons.  First of all 
it could be related to a direct virus induced endothelial dysfunction resulting in vascular 
disease.  This is the reason most commonly being postulated for HIV induced vasculopathy. 
Various mechanisms by which this endothelial dysfunction develops is being described in 
detail elsewhere. With respect to this, it is important to note that duration of HIV had 
showed some significant association to the development of PAOD in bivariate analysis. This 
could probably mean that repeated and persistent endothelial dysfunction could result from 
prolonged duration of HIV infection.  But this association has to be proved stronger in large 
scale studies with more number of patients.  
 
Another important distinction to be made is whether there is a difference of prevalence in 
patients who are receiving HAART in comparison those who have never received the same.  
This could probably help us prove a direct role of virus itself in the causation of PAOD. But 
this becomes difficult as most patients with HIV are being on treatment for the same and 
doing a comparative study in that setting may be challenging.  
 
CD4 count has been found to be a risk factor for development of PAOD.  Many studies 
including Periard etal (74) have shown that HIV patients with low CD4 counts have an 
increased risk of developing PAOD.  The cut off used has varied.  In our study also, a higher 
risk of developing PAOD was found in those patients with CD4 count <300 in comparison to 
those with CD4 counts >300.  But in multivariate analysis, it lost significance (p = 0.101). 
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Even then the risk (OR-1.93) was high.  This could mean that the endothelial dysfunction or 
the degree of inflammation which happens in the vessel could be more in those with a 
suppressed immune system.  Large scale studies are further required to strongly prove this 
association. 
 
Overall the study helped prove the higher prevalence of PAOD in HIV positive patients as 
described in limited western studies.  It also provided an insight into the possible specific 
risk factors which could be associated with development of PAOD in this population.  This 
will definitely help in formulating large scale epidemiological studies in this part of the 
world. 
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Conclusions 
 
1. Prevalence of peripheral arterial occlusive disease in HIV positive patients is about 8 %.  
This in comparison to data among general population is high.   
 
2. The risk factors for PAOD in HIV positive patients which attained statistical significance at 
the end of the study were; 
 
- Use of protease inhibitors 
- Duration of treatment with protease inhibitors  
 
3. In the univariate analysis, following risk factors were also found to be significant, but they 
did not correlate well in the multivariate analysis: 
 
            - Duration of HIV infection 
            - Treatment (HAART) duration 
            - CD4 count < 300   
 
4. Traditional risk factors for peripheral arterial occlusive disease (like DM, HTN, 
dyslipidaemia, smoking) were not contributing significantly to the causation of peripheral 
arterial occlusive disease in HIV positive population.  
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5. Risk factors associated with higher risk of PAOD in this population was not much different 
from that of western population.  But smoking, DM and age which attained statistical 
significance in many studies in the west were not significant in this study, even in the 
bivariate analysis.  
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Limitations 
 
1. Study was conducted by a postgraduate student.  Time constraints were the major 
limitation which prevented me from recruiting consecutive patients into the study.  
Hence the estimated prevalence might not reflect the true prevalence in the 
community.  Hence large scale community based epidemiological studies with more 
number of patients are required to estimate the true prevalence of this disease in 
HIV patients. 
 
2. Stigma of the patient – The stigma associated with HIV disease is more than what I 
thought.  This has played a major role in my study especially with respect to the 
blood investigations (especially lipid profile) and further evaluations.  Even though a 
large number of patients were on protease inhibitors, they never had a lipid profile 
tested.  Those patients especially who were positive for PAOD were offered lipid 
profile testing free of cost by providing fund from my study.  They were also referred 
to the Vascular Surgery Unit of our hospital for further evaluations and treatment.  
But the common reply I received was that “they cannot wait for that” or “cannot 
come for that tomorrow” or “someone might see them hanging around in hospital”.  
This has resulted in me not getting enough data to identify those who were having 
undiagnosed dyslipidemia which is a major risk factor for PAOD in any patients and 
especially in an HIV patient on protease inhibitors. 
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3. Confirmation of the disease – Even though ABPI and Toe pressures have good 
sensitivity and specificity in identifying clinically relevant occlusions of the vessels, 
they are not the gold standard for identification of PAOD.  It is the Doppler and angio 
studies which are considered the gold standards for detection of PAOD.  And more 
over they help us in identifying the level and nature of occlusion and help us plan the 
treatment.  But my study did not had a provision for Doppler or angiographic studies 
for the patients due to large finances included.  But those patients who were found 
to have PAOD from my study were referred to Vascular Surgery unit for further 
evaluations which included one of these gold standard tests.  But as I mentioned 
earlier, majority had not turned up for the same due to stigma from the disease and 
also due to the large cost involved in further evaluations and treatment. 
 
4. Temporal ambiguity – Peripheral arterial occlusive disease might have been 
presented in a particular HIV positive patient before he/she was diagnosed with HIV.  
So in those patients, whether HIV has contributed to the causation of PAOD may be 
difficult to predict.  This will remain a limitation of my study. 
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POTENTIAL FOR FURTHER RESEARCH 
 
1. This study probably is the first study of its kind from India addressing the problem of 
PAOD in HIV patients. This can help other researchers formulate similar studies which will 
definitely benefit our HIV population 
 
2. Time constraints of a postgraduate student limited the number of patients in the study. 
Same study can be continued further by including more number of patients.  This could 
strengthen the power of study as well. The setting provides enough and more patients to 
develop this into a large scale study. 
 
3. Study can also be extended into the community so as to help identify the true prevalence. 
ART registry in the ART clinic could help us identify all patients under the locality.  But it may 
be a cumbersome process to trace these patients to their locality especially with the 
amount of stigma they live with. 
 
4. More risk factors could be studied (like viral load, type of protease inhibitor) 
 
5. Studies could be framed so as to correlate an abnormal ABPI with Doppler findings.  This 
will prove those patients who truly have PAOD.  Even though the sensitivity of ABPI in 
diagnosing PAOD is high, it is only a screening tool and not a gold standard.  This study was 
limited by the fact that there was no provision for further evaluation of PAOD patients to 
prove true PAOD with the help of Doppler.  This was due to the constraints if the study 
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being a thesis.  Hence further research with more financial support could pave way for 
including Doppler confirmation of PAOD in those with an abnormal ABPI. 
 
6. Study was limited by the fact that, none of the patients who were diagnosed with PAOD 
could be given any treatment/interventions.  This needed confirmation, localisation of 
disease if it was confirmed and further investigations (CT/MR angio/ECHO).  There was no 
provision for these in this study for any of these.  Even though these were offered to all 
PAOD patients, most did not turn up to the vascular clinic, probably due to the large 
finances involved in all these.  And in an Indian setting, finance plays a major role in availing 
treatment. And this is of importance in this particular group since majority are unemployed 
(due to the social stigma which still prevail this part of the world). Hence studies which 
could incorporate higher evaluations and interventions if required need to be formulated 
for benefitting PAOD patients in this population. 
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Christian Medical College and Hospital, Vellore 
Department of General Surgery 
PATIENT INFORMATION SHEET - THE PAODH STUDY (Prevalence and risk factors of Arterial 
Occlusive Disease in HIV positive patients) 
 
1) WHAT IS HIV? HIV is a virus causing immune system breakdown in our body. There is no 
cure for this condition. But it can be treated well these days which can extend your life. 
2)  WHAT IS PERIPHERAL VASCULAR SYSTEM? The blood vessels which supplies and takes 
away blood from our legs and arms comprises peripheral vascular system 
3) WHAT IS PERIPHERAL ARTERIAL OCCLUSIVE DISEASE? A block in one or many of your 
peripheral artery(s) can stop the blood supply and hence nutrition to the leg/arm. This can 
develop slowly or suddenly in a short time.  
4) WHAT ARE ITS CONSEQUENCES? If there is a block to blood supply, then cells will die 
either slowly or suddenly. It can lead to skin changes, ulcers, pain in the leg while walking, 
loss of sensation, paresis and ultimately limb loss. 
5) HOW IS HIV RELATED TO THIS? HIV can affect your blood vessels badly in the way 
described above and can lead to the above consequences. So if you are screened early for 
the presence of “BLOCK” in your blood vessels, there are ways to rectify or modify the 
“BLOCK” 
6) WHAT IS THIS STUDY ABOUT?  This study will check the blood pressure in your arms and 
legs after resting and after a short stint of walking. It will then let you know whether you 
have a block in your blood vessels or not.  
7) WHAT ARE THE RISKS AND BENEFITS TO ME IF I TAKE PART? There are no risks involved 
in this study. Only benefits as this will detect a block in your blood vessels in short time with 
just few blood pressure measurements. 
8) WHAT NEXT IF THERE IS A BLOCK TO MY VESSEL? We will lead you to do further tests/ 
advice you to undergo corrective measures to remove block in blood vessel either with the 
help of medicines and or surgery.  
9) CAN I WITHDRAW FROM THE STUDY AFTER SIGNING CONSENT FORM? You can always 
withdraw from the study at any point of time 
10) WILL MY NAME AND PERSONAL DETAILS BE PUBLISHED/GIVEN TO A THIRD PARTY? Your 
name and personal details will be kept confidential.  
11) WHOM CAN I CONTACT IF I HAVE ANY MORE QUERIES? Dr. Suraj.S, Department.of 
General Surgery -IV during working hours or at  suraj.cmc@gmail.com/04162282441 
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Christian Medical College and Hospital, Vellore 
Department of General Surgery 
THE PAODH STUDY (Prevalence and risk factors of Arterial Occlusive Disease in 
adult HIV positive patients) 
Patient name:                                 Sex:                      Age:                      Hospital number:                              
Study code no:                                                                                                                                                        
Date:        
 
With regard to the procedure: 
I confirm that I have explained the indications, benefits and common risks. I have done this 
in terms and language which in my judgment is suited to the understanding of the patient. 
 
Name of the doctor: 
Signature with Employment no/registration number:                                                                         
 
Patient  
I voluntarily agree to take part in this study. 
The doctor named in this form has explained the benefits and risks of the proposed study to 
me. 
I voluntarily agree to be part of the above said study in person. 
I declare that I have read the information sheet provided to me regarding this study and 
have clarified any doubts that I had.  I do understand what HIV is and what are its after 
effects especially related to blood vessels. I understand the need for such a study and how it 
will be useful to myself and others having similar disease. 
I also understand that my participation in this study is entirely voluntary. I understand that I 
have full right to reject my participation or withdraw permission to continue at any time 
without affecting my usual treatment or my legal rights. 
I understand that I will not receive any other financial compensation. 
I understand that my identity will not be relieved in any information released to third 
parties or published. 
I agree to clinical photographs being taken during the course of my stay in hospital. I know 
that my identity will be protected and that this will be used only for educational purposes. 
I know that there lies a possibility of evaluations and or interventions based on the above 
said study which has its own benefits and risks which are clearly being explained to me by 
the doctor. I do understand that those evaluations and interventions will only be done if I 
voluntarily choose to undergo the same as it is not included as part of the current study I’m 
signing into. I also understand that the expenses of further tests or interventions will have 
to be borne by me. 
 
Patient:                    Name:                                      Signature:                    Date:                     
Investigator:           Name:                                       Signature:                    Date:                                     
Witness:                  Name:                                       Signature:                    Date:                       
120 
 
 
 
ANNEXURE 3 
 
 
 
 
 
PROFORMA 
 
 
 
 
 
 
 
 
 
121 
 
Christian Medical College, Vellore 
Department of General Surgery 
PROFORMA - THE PAODH STUDY (Prevalence and risk factors of Arterial Occlusive Disease 
in HIV positive patients) 
 
Name:                     Age:                 Sex: M/F (Circle appropriate) 
 
Hospital no:                Study Code no: 10001 
 
.SYMPTOMATOLOGY 
 
Claudication: Yes/No (Based on Edinburgh questionnaire)       Duration: ------ years/months/days 
Claudication distance  : ------  feet/meters/kilometers 
Site of claudication:  
Rest pain: Yes/No     Duration: ----- years/months/days 
Ulcers/gangrene/amputation: Yes/No (circle appropriately)      Duration: ---- years/days/months 
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RISK FACTORS 
 
Tobacco: Present/Absent    
PRODUCT YEARS OF USE 
  
  
  
                           
Alcohol: Present/Absent                                                            Years of use: 
Diabetes: Present/Absent                                                           Years: 
Hypertension: Present/Absent                                                   Years: 
Dyslipidemia: Present/ Absent                                                  Years: 
CVA/MI/ANGINA/ANEURYSMS: Present/Absent                Years: 
(Circle appropriately) 
Family history of any of above : Present/ Absent                     Years: 
 
PRIMARY DISEASE&TREATMENT DETAILS 
 
Duration since HIV diagnosed: --------- years/months 
 
Duration on ART: ------ years/months 
 
Regular on treatment: Yes/ No 
 
History of treatment with protease inhibitors (Either currently on it/was on it in past):Yes/No 
 
Duration of treatment with protease inhibitors: ----- years/months 
 
 
Details of treatment 
 
SL NO DRUG NAME DURATION(yrs/months) 
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CLINICAL PARAMETERS 
 
Height -                                       Weight –  
BMI -  
Pulse rate -                                   Blood pressure –  
 
Clinical pulses 
 
SITE RIGHT LEFT 
Radial   
Ulnar   
Brachial   
Femoral   
Popliteal   
Posterior tibial   
Dorsalis pedis   
Carotid   
Carotid bruit   
+++ bounding ++ Strong, + weak, - absent, c/m – Can’t be measured (amputated) 
 
LABORATORY INVESTIGATIONS 
 
Haemoglobin: 
 
Lipid profile: 
Total cholesterol: 
Triglyceride level: 
HDL cholesterol: 
LDL cholesterol: 
 
CD4 count :  
 
Serum albumin:  
 
PARAMETER MEASUREMENT 
 
PARAMETER RIGHT LEFT 
REST ABPI   
POST EXERCISE ABPI   
TOE PRESSURE (if needed)   
TBI (if needed)   
Name of investigator/doctor: 
Date and time: 
Signature: 
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NAME AGE SEX CLAUD DISTANCE REST PAIN CLI TOBACCO
Kannamma 45 1 1 2 0 0 0
Saraswathi 49 1 0 - - - 0
Kamala 55 1 0 - - - 0
Issac.D 40 0 0 - - - 0
Ramya 18 1 0 - - - 0
Dharman 58 0 1 3 0 0 1
Venkatesan 47 0 1 0.5 0 0 1
Saravanan 35 0 0 - - - 0
Aruna 46 1 0 - - - 0
Neelamaken 42 0 0 - - - 0
Ravichandran 49 0 0 - - - 0
Vino.S 26 1 1 1 0 0 0
Kamesh 47 0 1 1 0 0 0
Prabhavathy 30 1 0 - - - 1
Mohanbabu 52 0 1 0.1 0 0 1
H.Naidu 60 0 0 - - - 1
Omprakash 32 0 0 - - - 1
Andal 46 1 0 - - - 0
Janakiraman 40 0 0 - - - 0
Alice 45 1 0 - - - 0
Glory 44 1 0 - - - 0
Raja 45 0 0 - - - 0
Geetha 35 1 0 - - - 0
Baby 46 1 0 - - - 1
Anbu 47 0 0 - - - 0
Narayanamoorthy 42 0 0 - - - 0
Govindaraj 55 0 0 - - - 1
Balaji 40 0 0 - - - 1
Jyothi 35 0 0 - - - 1
Chennakrishna 44 0 0 - - - 0
Gopalan 50 0 1 0.5 0 0 0
Suresh 38 0 0 - - - 0
Sekar 47 0 0 - - - 1
Dharani 50 1 0 - - - 0
Shanthi 42 0 1 1 0 0 0
Jayakantha 39 0 0 - - - 0
Meenakshi 40 1 0 - - - 0
Latha 36 1 0 - - - 0
Dhandapani 37 0 0 - - - 0
Manogaran 48 0 0 - - - 0
Chitra 32 1 0 - - - 1
Chithra 35 1 0 - - - 0
Harikrishna 60 0 0 - - - 1
Arun Kr 29 0 0 - - - 0
Ravichandran 46 0 0 - - - 1
Jagan 37 0 0 - - - 1
Ravi 47 0 0 - - - 0
Vasantha Kr 32 0 0 - - - 0
Sankaraih 33 0 0 - - - 0
Basant.Kr 43 0 0 - - - 0
Palaniswamy 41 0 0 - - - 0
Narasimman 41 0 0 - - - 1
Siva 39 0 0 - - - 1
Arul.A 40 0 0 - - - 1
Selvam 43 0 1 1 0 0 0
Chithra 34 1 0 - - - 0
Savithri 39 1 0 - - - 0
Victor 49 0 1 1 0 0 0
Savithri 45 1 0 - - - 0
Ramesh 43 0 0 - - - 0
Kumuravalli 52 1 0 - - - 0
Padma 35 1 0 - - - 0
Velu 36 0 0 - - - 1
Santhi 42 1 0 - - - 0
Indhumathi 29 1 0 - - - 0
Chandran 36 0 0 - - - 0
Samsath.B 40 1 0 - - - 0
Thamara 32 1 0 - - - 0
Arunachalam 40 0 0 - - - 1
Shanthi 50 1 0 - - - 0
Geetha 37 1 0 - - - 0
Devaki 56 1 0 - - - 0
Sanjay 46 0 1 2 - - 1
Arunachalam 60 0 0 - - - 0
Arumugam 39 0 0 - - - 0
Ravi 38 0 0 - - - 0
Ravi 47 0 0 - - - 0
Venkatesan 43 0 0 - - - 1
J.Venkatalakshmi 42 1 0 - - - 0
Velmurugan 37 0 0 - - - 1
Madhaiyan 49 0 0 - - - 0
Venkataramanah 62 0 0 - - - 1
Samuel 36 0 0 - - - 1
Loganathan 46 0 0 - - - 1
K.Jyothi 42 1 0 - - - 0
Murugan 39 0 0 - - - 0
Revathi 29 1 0 - - - 0
Jagadeswari 38 1 0 - - - 0
Jothi 34 1 0 - - - 0
Easwari 42 1 0 - - - 0
Kavitha 35 1 0 - - - 1
Murugan 44 0 0 - - - 0
Shiv Kumari 44 1 0 - - - 0
Kavitha 44 1 0 - - - 0
Audiyappan 55 0 0 - - - 0
Bijay Shankar 45 0 0 - - - 1
Deenadayalan 40 0 0 - - - 1
Chinnabba 46 1 0 - - - 0
Tamilmani 53 0 0 - - - 0
A.Venkataram 30 0 0 - - - 0
Logesh 49 0 0 - - - 1
Ramu 34 0 0 - - - 0
Manju Gupta 35 1 0 - - - 0
Murali 39 0 0 - - - 0
Tanzila Bibi 40 1 0 - - - 0
H.S.Mondal 47 0 0 - - - 1
Meenatchi 48 1 0 - - - 0
Murthy 27 0 0 - - - 1
Thangadurai 40 0 0 - - - 1
Govindaraj 46 0 0 - - - 1
Malarvizhi 37 1 0 - - - 0
Anjaneyalu Reddy 55 0 0 - - - 0
Sasikala 21 1 0 - - - 0
Meenatchi 45 1 0 - - - 0
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Ratinakumari 39 1 0 - - - 0
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Janakiraman 40 0 0 - - - 0
Jagadheesh 46 0 0 - - - 0
Sudheer Kumar 42 0 0 - - - 0
Giridhar 48 0 1 1 0 0 0
Meena 36 1 0 - - - 0
Sreenivasa Reddy 46 0 0 - - - 1
Chitti Babu 47 0 0 - - - 1
Sridhar 49 0 0 - - - 0
Parimala 31 1 0 - - - 0
Clarence 42 0 0 - - - 0
Balamurugan 34 0 0 - - - 0
Indra 42 1 0 - - - 0
Suresh 33 0 0 - - - 0
Srinivasan 52 0 0 - - - 1
Kumar 49 0 0 - - - 0
Varadharajan 50 0 0 - - - 1
Suresh 34 0 0 - - - 0
Devika 46 1 0 - - - 0
Krishnan 54 0 0 - - - 0
Senthamarai 60 1 0 - - - 0
Mahalakshmi 28 1 0 - - - 0
Aanumakka 60 1 0 - - - 0
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Ranganathan 45 0 0 - - - 0
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Ramakrishna Yadav 48 0 1 1 0 0 0
Arun Raj 27 0 0 - - - 0
Rajalakshmi 42 1 0 - - - 0
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Srinivasa Naidu 40 0 0 - - - 0
Usha 34 1 0 - - - 0
Vijaya 32 1 0 - - - 0
Damodharan 40 0 0 - - - 0
Jouher 45 0 0 - - - 0
Selvi 45 1 0 - - - 0
Raja.M 29 0 0 - - - 0
Tamizharasu 40 0 0 - - - 0
Muthukrishnan 49 0 0 - - - 0
Sivakumar 42 0 0 - - - 0
Valarmathi 44 1 0 - - - 0
Kumaran 37 0 0 - - - 0
Lalitha 37 1 0 - - - 0
Arumugam 48 0 0 - - - 0
G.Ravi 44 0 0 - - - 1
Ganesh 48 0 0 - - - 0
Kumari 37 1 0 - - - 0
Govindaraj 33 0 0 - - - 1
Kesavan 46 0 1 0.5 0 0 0
Mannuswamy 69 0 0 - - - 0
Lavanya 30 1 0 - - - 0
Mahesh 40 0 0 - - - 0
Ramachandran 38 0 0 - - - 0
Kannan 43 0 0 - - - 1
Srinivasan 43 0 0 - - - 0
Manjula 34 1 0 - - - 0
Sumathi 40 1 0 - - - 0
Esther 37 1 0 - - - 0
Rajathi 34 1 0 - - - 0
Shobha 37 1 0 - - - 0
Sugumar.S 32 0 0 - - - 0
Siva 43 0 0 - - - 1
Shakila 46 1 0 - - - 0
Booma Devi 46 1 0 - - - 0
Jeyaraman 51 0 0 - - - 0
Murugaiyan 39 0 0 - - - 0
Chandrika 40 1 0 - - - 0
Subba reddy 59 0 0 - - - 0
Vanitha 38 1 1 1 0 0 0
Gunavathi 40 1 0 - - - 0
Srinivasan 50 0 0 - - - 1
Jothi 26 1 0 - - - 0
Veerammal 46 1 0 - - - 0
Andiappan 58 0 0 - - - 0
Anuj Singh 46 0 0 - - - 0
Solai 43 0 0 - - - 1
Kumar 32 0 0 - - - 0
Chithra.M 33 1 0 - - - 1
Arockiadas 70 0 0 - - - 1
Vairakannu 45 0 0 - - - 0
Balasubaiah 41 0 0 - - - 1
Kumari 38 1 0 - - - 0
Loganathan 41 0 0 - - - 0
Kumar 40 0 0 - - - 0
Arumugam 57 0 0 - - - 1
Suguna 35 1 0 - - - 0
Ananda Kumar 46 0 0 - - - 0
Kalpana 27 1 0 - - - 0
Kumar 36 0 0 - - - 0
Bharathi 47 1 0 - - - 0
Kotteswari 45 1 0 - - - 0
Saravanan 39 0 0 - - - 0
Thanjiyappan 38 0 0 - - - 0
Mohana 40 1 0 - - - 0
Munikannan 48 0 0 - - - 0
Murali 39 0 0 - - - 0
Jayashankar 47 0 0 - - - 1
Sigamani 29 0 0 - - - 0
Raja 42 0 0 - - - 0
Muniswamy 48 0 0 - - - 0
Saraswathi 48 1 0 - - - 0
Sivasangari 31 1 0 - - - 0
Venkatesan 40 0 0 - - - 1
Ganeshan 40 0 0 - - - 0
Subramanyam 38 0 1 0.5 0 0 0
Rathinavel 38 0 0 - - - 0
Lavanya 22 1 0 - - - 0
Krishnan 55 0 0 - - - 1
Prabha Rani 32 1 0 - - - 0
Govindaraj 42 0 0 - - - 0
Vijay 40 0 0 - - - 0
Jaya 33 1 0 - - - 0
Geetha 38 1 0 - - - 0
Mohan 42 0 0 - - - 0
Lucky 40 0 0 - - - 1
J.V.Lakshmi 42 1 0 - - - 0
Kousalya 33 1 0 - - - 0
Babu 48 0 0 - - - 1
Moorthy 47 0 0 - - - 0
Jeyakumar 39 0 0 - - - 1
Prabhakar Naidu 40 0 0 - - - 0
Kavitha 28 1 0 - - - 0
Gajalakshmi 43 1 0 - - - 0
Selvi 38 1 0 - - - 0
Bharathi 42 1 0 - - - 0
Sathyalakshmi 40 1 0 - - - 0
Girija 37 1 0 - - - 0
Kalaiselvi 48 1 0 - - - 0
Manimegalai 28 1 0 - - - 0
Jennima.F 29 1 0 - - - 0
Neelavalli Shobhana 27 1 0 - - - 0
Malarkodi 47 1 0 - - - 0
Kasthuri 35 1 0 - - - 0
N.Mahesh 33 0 0 - - - 0
Ganeshan 59 0 0 - - - 1
Somasundaram 49 0 0 - - - 0
Chitra 35 1 0 - - - 0
Boopathi 40 0 0 - - - 0
Rajeswari 40 1 0 - - - 0
Shankar 49 0 0 - - - 0
Rajesh Kr 32 0 1 1 - - 1
Sujata 36 1 0 - - - 0
Geetha 36 1 0 - - - 0
Shanthi 40 1 0 - - - 0
Renuka 48 1 0 - - - 0
Bharathi 40 1 0 - - - 0
Arun.S 27 0 0 - - - 0
Sumathi 47 1 0 - - - 0
Ponnuswamy 51 0 0 - - - 1
Shanthi 53 1 0 - - - 0
Premlatha 36 1 0 - - - 0
Ezhumalai 45 0 0 - - - 0
Banumathi 55 0 0 - - - 0
Dhamodharan 45 0 0 - - - 0
Raman 49 0 0 - - - 0
Thulukkanan 45 0 0 - - - 0
Sathish Kr 38 0 0 - - - 0
Nagarajan 43 0 0 - - - 0
Thirumugam 51 0 0 - - - 0
Renuka 36 1 0 - - - 0
Kalaivani 50 1 0 - - - 0
Mohan 44 0 0 - - - 0
Parimala 43 1 0 - - - 0
Banumathi 37 1 0 - - - 0
Pownammal 50 1 0 - - - 0
Amsa 50 1 0 - - - 0
Babu 43 0 0 - - - 0
Srinivasan 41 0 0 - - - 0
Vanitha 36 1 0 - - - 0
Pandiyan 49 0 0 - - - 0
Murugan 41 0 0 - - - 1
Valarmathi 45 1 0 - - - 0
Manogaran 53 0 0 - - - 0
Srinivasan 47 0 0 - - - 1
Rajalakshmi 24 1 0 - - - 0
Palani 32 0 0 - - - 0
Bhuvaneswari 36 1 0 - - - 0
Manjula 40 1 0 - - - 0
Amsa 40 1 0 - - - 0
Velmurugan 40 0 0 - - - 0
Mallesh 39 0 0 - - - 0
Sumathi 42 1 0 - - - 0
Reshma 37 1 0 - - - 0
Malarkodi 35 1 0 - - - 0
Clement 45 0 0 - - - 0
Chitti Babu 42 0 0 - - - 0
Gandhi 34 0 0 - - - 1
Annapoorni 55 1 0 - - - 0
Suseela 39 1 0 - - - 0
Syamala 42 1 0 - - - 0
Ealumalai 43 0 0 - - - 0
Revi 41 0 0 - - - 0
Lakshmi 33 1 0 - - - 0
Geetha 41 1 0 - - - 0
Thirumal 25 0 0 - - - 0
Ganapathy 48 0 0 - - - 1
Venugopal 58 0 0 - - - 1
Prabhavathy 32 1 0 - - - 0
Ramu 36 0 0 - - - 0
Kasthuri 53 1 0 - - - 0
Lokeswari 31 1 0 - - - 0
Balu 64 0 0 - - - 1
Srinivasan 45 0 0 - - - 1
Chitra 35 1 0 - - - 0
Meenkodi 23 1 0 - - - 0
Ramani 50 1 0 - - - 0
Elangovan 37 0 0 - - - 0
Meenakshi 40 1 0 - - - 0
Jyothi 43 0 0 - - - 1
Ramesh Babu 43 0 0 - - - 1
Varadhan 60 0 1 1 1 0 1
Jeyanthi 32 1 0 - - - 0
Srinivasan 61 0 0 - - - 1
Sivakumar 40 0 0 - - - 0
Girija 48 1 0 - - - 0
Venkatesh 43 0 0 - - - 1
Amulu 43 1 0 - - - 0
Sheela 42 1 0 - - - 0
Tamarai Selvi 44 1 0 - - - 0
Shimla Devi 45 1 0 - - - 1
Shaik Md Ali 46 0 0 - - - 1
Siva 46 0 0 - - - 0
Venkatesan 49 0 0 - - - 0
Selvam 55 0 0 - - - 1
Prema 31 1 0 - - - 0
Mical 47 0 0 - - - 0
Sanjay Bajaj 31 0 0 - - - 0
Sivaprakasam 55 0 0 - - - 0
Dhanalakshmi 28 1 0 - - - 0
Kalaivani 23 1 0 - - - 0
Murthy 35 0 0 - - - 0
T.S.Rao 37 0 - - - - 0
Prameela 41 1 0 - - - 0
Emi.M 22 0 0 - - - 0
Nagaraj 36 0 0 - - - 1
Sumathi 31 1 0 - - - 0
ALCOHOL DM HTN DYSLIPID IHD/ACS CVA/TIA F/H VAS DISHIV DUR(Mo)RX DUR
0 0 0 1 0 0 0 96 48
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 36 36
1 0 0 1 1 0 0 5 3
0 1 1 0 0 0 0 60 60
0 0 0 0 0 0 0 12 8
0 0 0 0 0 0 0 3 3
0 0 0 0 0 0 1 36 36
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 24 12
1 0 1 0 0 0 0 12 12
0 0 0 0 0 0 0 3 3
1 1 1 1 0 0 0 2 1.5
1 0 1 0 0 0 0 12 12
1 0 0 0 0 0 0 18 12
0 0 0 0 0 0 0 6 6
0 0 0 0 0 0 0 36 36
0 0 1 0 0 0 0 36 36
0 0 0 0 0 0 0 132 132
0 0 0 0 0 0 0 156 4
0 0 0 0 0 0 0 84 24
1 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 12 12
0 0 1 0 0 0 0 72 72
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 2 2
1 0 0 0 0 0 0 8 8
0 0 0 0 0 0 0 0.25 -
0 1 0 0 0 0 0 264 72
0 0 0 0 0 0 0 96 96
1 0 0 0 0 0 0 1 0.5
0 0 0 0 0 0 0 108 36
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 48 -
0 0 0 0 0 0 0 0.25 -
0 0 0 0 0 0 0 48 24
0 0 0 0 0 0 0 1 -
0 0 0 0 0 0 0 12 4
0 0 0 0 0 0 0 1 0.5
0 0 0 0 0 0 0 1 0.5
0 0 0 0 0 0 0 6 1
1 0 0 0 0 0 0 3 -
0 0 0 0 0 0 0 2 0.25
0 0 0 0 0 0 0 228 120
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 5 1
0 0 0 0 0 0 0 36 -
1 0 1 0 0 0 0 1 -
0 0 0 0 0 0 0 72 72
1 1 0 1 0 0 0 108 108
0 0 0 0 0 0 0 120 96
0 0 0 0 0 0 0 84 84
0 0 1 0 0 0 0 12 12
0 0 0 0 0 0 0 7 7
0 0 1 0 0 0 0 156 156
0 1 0 0 0 0 0 48 0.25
0 0 0 0 0 0 1 60 60
0 0 1 0 0 0 0 24 24
0 0 0 0 0 0 0 120 120
1 0 0 0 0 0 1 18 18
0 0 0 0 0 0 0 7 7
0 0 0 0 0 0 0 48 48
1 0 1 0 0 0 0 36 0.03
0 0 1 0 0 0 0 12 12
0 0 0 0 0 0 0 36 0.03
1 0 0 0 1 0 0 24 24
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 36 36
1 0 0 0 0 0 0 36 36
0 0 1 0 0 0 0 108 108
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 132 132
0 0 0 0 0 0 0 132 132
0 0 0 0 0 0 0 8 8
0 0 0 0 0 0 0 108 24
1 0 0 0 0 0 0 72 5
0 0 0 0 0 0 0 72 -
0 1 0 0 0 0 0 108 108
1 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 4 4
0 0 1 0 0 0 0 72 72
0 0 0 0 0 0 0 4 4
0 0 0 0 0 0 0 1 0.5
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 180 48
0 0 0 0 0 0 0 120 -
1 0 0 0 0 0 0 120 -
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 30 30
0 0 0 0 0 0 0 36 12
1 0 0 0 0 0 0 24 -
1 0 0 0 0 0 0 180 180
0 0 0 0 0 0 0 2 -
0 0 0 0 0 0 0 6 6
0 0 0 0 0 0 0 48 -
0 1 1 1 0 0 0 120 -
0 0 0 0 0 0 0 48 48
0 0 1 0 0 0 0 0.66 -
0 0 1 0 0 0 0 18 -
0 0 0 0 0 0 0 180 48
0 0 0 0 0 0 0 180 180
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 36 24
0 0 0 0 0 0 0 120 24
0 0 0 0 0 0 0 6 6
0 0 0 0 0 0 0 3 2
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 9 9
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 72 0.26
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 18 18
0 0 0 0 0 0 0 96 12
0 0 0 0 0 0 0 96 96
0 0 1 1 0 0 0 72 72
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 12 12
0 1 0 0 0 0 0 12 12
0 0 0 0 0 0 0 3 3
0 0 0 0 0 0 0 18 18
1 0 0 0 0 0 0 18 18
0 1 1 0 0 0 1 36 36
0 0 0 0 0 0 0 36 36
0 0 0 0 0 1 1 4 -
0 0 0 0 0 0 0 13 13
0 0 0 0 0 0 0 18 18
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 36 -
0 0 0 0 0 0 0 1 1
0 0 1 0 0 0 0 60 60
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 60 6
0 0 0 0 0 0 0 48 48
1 0 0 0 0 0 0 6 4
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 96 24
0 0 0 0 0 0 0 12 12
1 0 0 0 0 0 0 30 30
0 0 0 0 0 0 0 9 9
0 0 0 0 0 0 0 120 84
0 0 0 0 0 0 0 96 96
0 0 1 0 0 0 0 72 72
0 0 0 0 0 0 0 108 108
0 0 0 0 0 0 0 17 17
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 16 16
0 0 0 0 0 0 0 29 29
0 0 0 0 0 0 0 17 17
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 96 72
0 0 0 0 0 0 0 24 24`
0 0 0 0 0 0 0 120 120
0 0 0 0 0 0 0 48 48
0 1 0 0 0 0 0 14 14
0 0 1 0 0 0 0 96 48
0 1 1 0 0 0 0 96 72
0 0 0 0 0 0 0 72 72
1 0 1 0 0 0 0 48 48
0 0 1 0 0 0 0 120 84
0 1 0 0 0 0 0 0.5 0.5
0 0 0 0 0 0 0 29 29
0 0 0 0 0 0 0 64 64
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 60 37
1 0 1 0 0 0 0 84 30
0 0 1 0 0 0 0 60 60
0 0 1 0 0 0 0 24 24
0 0 0 0 0 0 0 96 96
0 0 0 0 0 0 0 24 3
0 0 1 0 0 0 0 25 25
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 60 60
0 1 0 0 0 0 0 60 60
0 0 0 1 0 0 0 120 120
1 0 0 0 0 0 0 144 108
0 0 0 0 0 0 0 124 124
0 0 0 0 0 0 36 0.33
0 0 0 0 0 0 0 120 120
1 1 0 0 0 0 0 24 24
0 0 1 0 0 0 0 120 120
0 0 1 1 0 0 0 60 60
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 7 7
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 21 21
0 0 0 1 0 0 0 120 96
0 0 0 0 0 0 0 168 156
0 0 0 0 0 0 0 41 41
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 0.5 0.5
0 0 0 0 0 0 0 24 24
1 0 0 0 0 0 0 132 132
0 1 0 0 0 0 0 40 36
0 0 1 0 0 0 0 120 30
0 1 1 0 0 0 0 144 36
0 0 1 0 0 0 0 12 1.5
0 0 1 0 0 0 0 15 15
0 0 0 0 0 0 0 48 48
1 0 0 0 1 0 0 96 96
0 0 0 0 0 0 0 204 72
0 0 0 0 0 0 0 240 12
1 0 0 0 0 0 0 48 48
0 0 1 0 0 0 0 48 48
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 5 5
0 0 0 0 0 0 0 96 72
0 0 0 0 0 0 0 5 5
1 0 0 0 0 0 0 4 2
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 120 120
0 0 0 0 0 0 0 26 26
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 156 84
0 0 0 0 0 0 0 84 72
0 0 0 0 0 0 0 24 24
1 1 0 1 0 0 0 120 120
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 14 14
0 0 1 1 0 0 0 84 84
0 0 1 0 0 0 0 96 96
0 0 0 0 0 0 0 24 24
0 0 1 1 0 0 0 72 72
0 0 0 1 0 0 0 120 18
0 1 0 0 0 0 0 240 192
0 0 1 0 0 0 0 24 24
0 0 0 0 0 0 0 53 36
0 0 0 0 0 0 0 60 48
0 1 1 1 0 0 0 120 120
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 120 24
0 0 0 0 0 0 0 96 84
0 0 0 0 0 0 0 18 12
1 0 1 0 0 0 0 48 48
0 0 1 0 0 0 0 60 60
0 0 1 0 0 0 0 120 -
0 0 0 0 0 0 0 96 96
0 0 0 0 0 0 0 6 4
0 0 0 0 0 0 0 192 24
0 0 0 0 0 0 0 6 6
0 0 0 0 0 0 0 2 2
0 0 0 0 0 0 0 48 24
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 18 18
0 0 0 0 0 0 0 132 120
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 72 72
1 0 0 0 0 0 0 24 24
0 1 1 1 0 0 1 168 60
0 1 1 1 0 0 0 48 48
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 8 8
0 0 1 0 0 0 0 48 48
0 0 1 0 0 0 0 240 96
0 0 0 0 0 0 0 120 27
1 0 0 0 0 0 0 18 18
0 0 1 0 0 0 0 72 72
0 0 0 0 0 0 0 10 4
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 2 0.5
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 60 60
1 1 0 1 0 0 0 1.5 1.5
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 16 16
0 0 0 0 0 0 1 27 27
1 0 0 0 0 0 0 22 22
1 0 1 0 0 0 0 75 75
1 0 0 0 0 0 0 108 20
1 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 56 56
0 0 0 0 0 0 0 58 58
0 0 0 0 0 0 0 24 18
0 0 0 0 0 0 0 40 40
0 0 1 0 0 0 0 84 84
0 0 1 0 0 0 0 108 108
0 0 0 0 0 0 0 66 66
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 12 -
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 3 3
0 0 0 0 0 0 0 2 2
0 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 28 28
1 0 0 0 0 0 0 18 18
0 0 0 0 0 0 0 52 52
0 0 0 0 0 0 0 60 -
0 0 1 0 0 0 0 60 0
1 0 0 0 0 0 0 1 1
0 0 0 0 0 0 0 3 0.5
0 1 0 1 0 0 0 168 120
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 42 42
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 120 27
0 0 0 0 0 0 0 12 12
0 1 1 0 0 0 0 36 36
0 0 0 0 0 0 0 72 72
0 0 1 0 0 0 0 17 17
0 0 0 0 0 0 0 96 96
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 180 29
0 0 0 0 0 0 0 37 37
0 0 0 0 0 0 0 27 27
1 0 1 0 0 0 0 24 24
0 0 0 0 0 0 0 8 7
0 1 1 0 0 0 0 120 108
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 120 120
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 36 36
0 0 1 0 0 0 0 60 60
0 0 0 0 0 0 0 108 108
0 0 0 0 0 0 0 7 7
0 1 0 0 0 0 0 39 39
0 0 0 0 0 0 0 60 60
0 1 0 0 0 0 0 48 48
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 96 96
1 0 0 0 0 0 0 29 29
0 0 0 0 0 0 0 204 12
0 0 0 0 0 0 0 60 60
1 0 0 0 0 0 1 79 79
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 96 36
0 0 0 0 0 0 0 60 60
0 1 0 0 0 0 0 120 66
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 108 72
0 0 0 0 0 0 0 50 50
0 0 1 0 0 0 0 96 60
0 0 0 0 0 0 0 108 108
0 0 0 0 0 0 0 84 84
1 0 0 0 0 0 0 48 48
1 0 0 0 0 0 0 72 72
0 1 0 0 0 0 0 36 36
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 204 60
1 0 0 0 0 0 0 144 144
1 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 48 12
0 0 0 0 0 0 0 168 48
0 0 0 0 0 0 0 48 48
1 0 0 0 0 0 0 240 144
0 1 1 0 0 0 0 60 60
0 0 0 0 0 0 1 24 24
0 0 0 0 0 0 0 108 108
0 0 0 0 0 0 0 72 72
0 0 0 0 0 0 0 72 24
0 0 0 0 0 0 0 48 48
1 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 120 36
0 0 0 0 0 0 0 24 24
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 96 30
0 0 0 0 0 0 0 48 7
1 0 0 0 0 0 0 156 84
1 0 0 0 0 0 0 48 48
1 0 1 0 0 0 0 72 72
0 0 0 0 0 0 0 108 24
0 1 1 0 0 0 0 72 72
0 0 0 0 0 0 0 108 96
0 0 0 0 0 0 0 36 36
1 0 0 0 0 0 0 12 12
0 0 0 0 0 0 0 108 60
0 0 0 0 0 0 0 36 36
0 0 0 0 0 0 0 30 30
0 0 0 0 0 0 0 48 48
0 0 0 0 0 0 0 12 12
1 0 0 0 0 0 0 132 48
1 0 1 0 0 0 0 84 84
1 0 0 0 0 0 0 288 36
0 0 0 0 0 0 0 39 39
0 1 0 0 0 0 0 144 144
0 0 0 0 0 0 0 3 3
0 0 0 0 0 0 0 76 76
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 62 60
0 0 0 0 0 0 0 60 60
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 84 84
0 0 0 0 0 0 0 26 26
0 0 0 0 0 0 0 19 19
0 0 0 0 0 0 0 72 24
PI? DUR PI DRUG DET HT WT BMI PR BP PULSES
0 - AZ/3T/NV 147 50.5 23.27 76 120/80 ++
1 6 TD/3T/NV 157 48.6 19.76 72 110/70 ++
0 - AZ/3T/NV 142 38.4 19.1 76 116/70 ++
0 -  AZ/3T/NV 170 55 19.03 80 130/90 ++
0  - D4T/3T/NV 143 43.8 21.47 84 100/66 ++
0  - AZ/3T/NV 163 55.6 20.98 80 128/74 ++
0  - AZ/3T/NV 168 62.8 22.16 68 152/100 ++
0  - AZ/3T/NV 164 51.5 19.2 72 120/72 ++
0  - AZ/3T/NV 157 58.3 23.69 76 118/80 ++
0  - AZ/3T/NV 170 74.7 25.8 92 118/68 ++
1 3 TDF/EFV 170 39.1 15.2 92 108/52 PT L +
0  - Z/L/E 153 59 25.2 80 90/60 PT B/L +
1 12 TD/3T/EFV 172 54 18.3 100 150/90 PT B/L +
0  - AZ/3T/NV 162 53 20.22 96 90/60 ++
0  - AZ/3T/NV 170 73 25.26 76 120/70 L PA,PED -
0 - ZLN 170 45 15.57 100 90/60 ++
0 - ZLN 170 65 22.49 80 140/70 ++
0 - ZLN 154 35 14.76 80 122/70 ++
0  - ZLN 180 60 18.51 68 130/70 ++
0  - ZLN 154 63 26.6 88 160/100 ++
0  - AZT/3T/EFV 148 54 24.7 68 130/70 PT,DP B/L +
0  - ZLN 172 72 24.7 76 116/72 ++
0  - ZLN 157 53 21.54 100 102/60 ++
0  - SLN 163 46 17.36 80 140/80 ++
0  - ZLN 170 63 21.8 64 106/60 ++
0  - ZLN 167 70 25.18 80 140/70 ++
0  - ZLN 172 49 16.7 78 116/60 ++
0  - AZ/3T/NV 176 75 24.27 80 120/70 R PT +
0  - AZ/3T/NV 166 55 20 80 120/72 ++
- - - 170 50 17.3 88 124/70 ++
0  - AZ/3T/NV 158 58 23.29 88 140/80 ++
0  - AZ/3T/NV 165 73 26.83 76 140/90 ++
0  - ZLN 152 47 20.34 88 130/70 ++
0 - ZLN 150 47.9 21.3 84 122/70 ++
0  - ZLN 154 73 30.8 84 138/82 ++
0  - SLN 158 76 21.28 76 120/72 ++
-  - - 152 41 17.75 68 128/70 R DP - L DP +
 -  -  - 168 50 17.73 76 102/60 B/L DP +
0  - ZLN 170 55 19.03 68 100/60 ++
- - - 164 70 26.12 76 140/70 ++
1 4 TLN 152 43 18.69 76 118/68 ++
0 - ZLN 152 35 15.21 96 124/72 ++
0 - ZLN 156 40 16.46 68 96/60 ++
0 - ZLE 172 85 28.81 80 120/70 ++
- - - 170 45 15.57 120 100/64 ++
0 - ZLE 175 57 27.66 92 112/74 ++
1 96 NZVRIT 172 47 15.93 76 116/70 ++
1 11 ETENEMTRI 176 72 23.3 76 120/70 ++
0 - TLE 150 53 21.81 94 128/70 PT +
- - - 171 44 15.06 80 118/76 ++
- - - 175 96 31.36 88 148/90 B/L PT +
0 - ZLN 170 54 18.69 76 102/60 R DP +
0 - ZLE 160 73 28.6 72 120/80 ++
0 - ZLE 174 69 22.84 80 130/90 ++
0 - SLN 164 80 29.74 84 110/60 R U&L +,L PT+
1 12 TLN 156 82 33.7 78 134/110 L DP&PTA + 
1 7 TLE 152 34 23.4 72 100/80 ++
0 - ZLN 165 64 23.5 80 122/70 ++
0 - ZLN 143 57.3 27.9 68 108/70 ++
1 12 TLN 164 43.7 16.2 92 138/84 PA&DP+,PTA-
0 - ZLN 150 47.1 20.9 86 170/110 ++
1 24 TLN 148 45 20.5 78 122/64 ++
0 - ZLE 170 62.4 23.5 68 128/7 ++
1 7 TLN 153 45.1 19.2 100 138/82 ++
0 - ZLN 152 46.7 20.2 88 128/78 ++
0 - ZLN 160 70 27.3 84 152/76 ++
1 12 TLE 153 61.1 26.1 88 152/80 ++
0 - ZLN 156 70 20.8 76 138/68 ++
1 24 TLE 158 43 17.2 76 122/64 ++
1 12 TLN 150 57.1 25.3 86 98/56 ++
0 - ZLN 159 65 25.7 72 148/90 ++
1 36 TLN 158 51.9 20.8 86 132/64 B/L PT +
1 12 TLE 162 57.1 21.7 68 96/50 ++
0 - ZLE 160 51.2 22.7 58 150/90 ++
0 - ZLE 170 71.1 24.6 82 112/64 ++
0 - ZLN 140 64 32.7 78 140/66 ++
0 - ZLN 164 62 23.1 80 120/64 ++
1 8 TLE 175 62.1 20.2 76 120/70 ++
0 - ZLN 156 61 25.1 78 118/80 ++
0 - ZLN 163 48 18.1 96 104/68 ++
- - - 170 71 24.6 100 140/90 ++
1 1 TRA 168 64 22.7 64 150/90 ++
0 - ZLN 165 52 19.1 100 140/92 ++
1 4 TLN 172 81.6 27.6 80 120/80 ++
1 4 TLN 172 58.9 19.9 76 160/100 ++
0 - ZLN 169 69.7 24.5 80 132/80 ++
0 - ZLN 155 49.1 20.4 78 104/60 ++
0 - ZLN 170 74 25.6 92 110/70 ++
1 12 TLE 165 60 22.05 76 130/70 ++
0 - ZLE 164 43.8 16.28 68 108/64 ++
- - - 152 56 24.24 80 118/60 ++
- - - 176 68 21.96 76 140/92 ++
1 0.5 TLN 158 40 16.21 92 100/54 ++
1 30 TLE 154 50.5 21.3 96 108/58 ++
0 - ZLN 156 57.2 23.7 88 140/72 ++
- - - 170 45 14.38 78 122/80 ++
0 - ZLN 172 40 13.56 80 100/50 ++
- - - 164 52 19.33 84 120/80 ++
1 2 TLE 169 49 17.13 76 150/90 ++
- - - 177 74 23.64 80 126/72 ++
- - - 180 96 29.63 80 150/82 ++
0 - ZLE 161 53 20.46 72 104/58 ++
- - - 158 60 24 88 160/90 ++
- - - 152 70 30.3 84 152/90 ++
0 - ZLN 150 50 22.2 86 100/60 ++
0 - ZLN 176 56 18.12 74 132/80 ++
0 - ZLE 164 55 20.45 78 110/70 ++
0 - ZLN 160 63.5 24.8 84 124/70 ++
1 12 TLN 168 86 30.49 88 124/70 ++
0 - ZLN 166 67 24.36 70 146/68 ++
0 - ZLE 169 63 22.02 68 128/76 ++
1 6 TLE 171 80 27.39 88 130/90 ++
1 2 TLE 151 43.9 19.25 74 98/50 B/L PTA +
1 24 TLE 146 34.3 16.1 92 100/50 ++
0 - ZLN 150 46.9 20.84 76 140/72 ++
0 - ZLE 155 47.5 19.88 74 116/60 ++
0 - ZLE 169 65.1 22.84 96 120/76 ++
1 0.26 TLE 152 88.9 38.48 84 142/90 B/L PT&DP +
0 - ZLN 147 40.5 18.75 82 110/62 ++
1 18 TLE 156 62.5 25.76 76 124/72 ++
1 12 TLE 166 70.6 25.67 84 110/60 ++
0 - ZLN 164 72.1 26.8 88 142/80 ++
0 - ZLN 172 78.6 26.64 80 180/100 ++
1 24 TLN 153 41.2 17.6 70 146/68 ++
1 12 TLN 148 49 22.37 72 120/68 ++
0 - ZLN 172 64 21.69 66 126/70 ++
1 2 TLN 145 40.7 19.38 74 122/60 ++
1 3 TLE 157 57.6 23.41 86 120/72 ++
1 18 TLE 161 59.3 22.89 80 160/80 ++
0 - ZLN 160 57.2 22.34 84 110/60 ++
0 - ZLN 168 62.5 22.1 76 128/80 ++
- - - 175 60 19.6 104 124/82 ++
0 - ZLN 167 60.7 21.75 68 112/64 ++
0 - ZLN 168 67.4 26.3 70 130/84 ++
1 12 TLE 164 73 27.13 86 120/70 ++
- - - 162 90 34.35 72 102/64 ++
1 1 TLE 158 63.9 25.66 76 122/80 ++
1 60 TLN 179 51.8 16.2 80 180/100 ++
1 24 TLN 160 58 20.5 88 124/76 ++
0 - ZLE 149 36 16.2 72 110/72 ++
0 - ZLN 165 74.8 27.5 68 142/80 ++
1 4 TLE 174 68.4 22.6 68 128/68 ++
1 6 TLN 152 49 21.2 76 140/90 ++
1 24 TLE 175 61 19.9 74 118/66 ++
0 - ZLE 158 65.5 26.2 88 104/50 ++
0 - ZLN 158 46.7 18.7 70 108/70 ++
0 - ZLE 164 52.8 19.6 72 126/60 ++
0 - ZLN 168 47 16.7 76 116/58 ++
0 - ZLN 168 49.8 17.6 78 126/66 ++
1 12 TLN 168 77.5 27.5 64 176/98 ++
0 - ZLN 178 72.8 23 78 130/82 ++
0 - ZLN 165 63.5 23.3 74 160/84 ++
0 - ZLN 168 71 25.2 80 118/74 ++
0 - ZLN 153 51 21.8 84 120/70 ++
1 5 TLE 158 49.4 19.8 80 126/74 PT,DP +, RU+
0 - ZLE 170 68.6 23.7 80 120/70 ++
1 5 TLE 160 55 21.5 74 124/64 ++
1 24 TRA 163 57 21.5 90 132/78 ++
1 5 TLN 163 71.3 20.8 68 120/68 ++
0 - ZLN 145 47.1 22.4 80 124/66 ++
1 18 TLE 168 43.8 15.5 74 126/72 ++
0 - ZLN 166 59.3 21.5 72 110/70 ++
0 - ZLE 170 67.4 23.3 76 138/80 ++
1 12 TLN 171 80 27.4 74 154/90 ++
1 6 TLN 167 57.9 20.8 80 140/78 ++
0 - ZLN 156 45.4 18.7 68 128/68 ++
0 - ZLN 166 62.9 22.9 80 122/70 ++
0 - ZLN 160 52 20.3 82 142/86 ++
0 - ZLN 165 66 24.3 74 138/72 ++
0 - ZLN 158 56.3 20.1 90 130/68 ++
1 30 TLN 145 70.1 25.7 82 138/76 ++
1 2 TLE 160 47 18.4 76 102/64 ++
1 84 TLN 164 60.7 22 74 130/68 ++
0 - ZLN 168 73.9 26.2 76 140/80 ++
1 7 TLN 172 62.5 21.1 64 150/84 ++
0 - ZLE 164 61.5 22.9 78 162/90 ++
1 20 TLE 167 66.7 23.9 74 160/100 ++
1 24 TRA 173 70 23.4 84 138/76 ++
1 3 TLE 150 64.6 28.7 74 126/80 ++
0 - ZLN 166 79.5 28.9 80 162/92 ++
0 - ZLN 158 52.3 21 86 132/70 ++
1 24 TLE 148 50 22.8 80 116/70 ++
0 - ZLN 157 40 16.1 68 140/84 ++
0 - ZLN 174 65.8 21.7 84 118/76 ++
1 2 TLN 150 39.2 17.4 66 102/58 ++
0 - ZLN 165 49.5 18.4 80 114/72 ++
0 - ZLE 167 62 22.2 76 140/80 ++
1 6 TLE 164 56.8 21.1 72 110/68 ++
1 24 TLE 172 49.6 16.9 76 120/70 ++
0 - ZLN 163 60 22.6 78 170/100 ++
0 - ZLE 160 62.7 24.5 82 180/98 ++
1 12 TLN 173 86 28.7 88 144/80 ++
1 7 TLN 164 49 18.2 90 100/68 ++
0 - ZLN 172 72.7 24.6 82 132/78 ++
1 24 TLE 165 67.5 24.8 80 156/82 ++
1 21 TLE 146 33.5 15.7 96 128/84 ++
1 8 TLN 145 45 21.4 80 122/68 ++
0 - ZLN 170 67.4 23.3 78 140/90 ++
1 12 TLN 161 46.5 17.9 80 118/76 ++
0 - ZLN 161 49.2 18.9 94 120/64 ++
0 - ZLN 168 70 27.5 80 140/86 ++
0 - ZLN 172 81.4 24.8 76 150/88 ++
0 - ZLN 147 36.9 17.1 66 100/50 ++
0 - ZLE 164 49 18.2 78 130/78 ++
1 42 TRA 170 61.2 21.2 84 140/92 ++
0 - ZLE 164 48.8 17.8 74 120/58 ++
0 - ZLN 175 78.2 25.5 76 162/96 ++
1 24 TLN 152 58 25.1 82 160/82 ++
1 1.5 TLE 171 60 20.5 88 160/88 ++
1 14 TLE 157 49 19.9 74 160/80 ++
1 48 TLN 158 47.4 18.8 80 124/76 ++
1 36 TRA 160 53.3 20.7 74 120/64 ++
0 - ZLE 163 60.4 22.6 76 122/72 ++
0 - ZLE 142 43.8 21.7 82 120/66 B/L PT+
1 24 TLE 169 51.5 17.9 78 110/64 ++
0 - ZLE 168 67.5 23.7 84 176/102 ++
0 - ZLN 158 45.5 18.4 80 136/72 ++
0 - ZLE 157 42.6 17 100 100/56 ++
0 - ZLN 160 59.7 23.4 76 160/90 ++
0 - ZLE 164 46.7 17.5 86 120/74 ++
0 - ZLE 169 60.7 21.4 78 122/70 ++
1 60 TLE 163 64.6 24.1 76 140/90 ++
1 24 TLE 156 34.4 14.4 94 140/80 ++
0 - ZLE 145 43.9 20.9 86 118/60 ++
0 - ZLN 155 48.2 20 74 138/68 ++
0 - ZLN 154 48 20.2 82 120/60 ++
0 - ZLN 151 69.3 30.7 80 120/68 ++
0 - ZLN 174 79.6 26.4 80 150/80 ++
0 - ZLN 160 72.2 28.1 74 126/78 ++
1 3 TLN 147 50.7 23.6 72 110/58 ++
1 12 TLN 152 48 20.8 80 120/60 ++
0 - ZLN 166 63.6 23.2 78 160/90 ++
1 12 TRA 167 78.5 28.3 80 182/100 ++
0 - ZLE 152 48.7 21.2 76 128/68 ++
0 - ZLN 161 49.8 19.3 82 154/90 ++
1 18 TLE 152 72 31.2 78 120/76 ++
0 - ZLN 152 53.3 23.4 76 140/70 ++
0 - ZLN 175 66.5 21.7 76 150/90 ++
0 - ZLN 146 55.5 27.1 86 100/60 ++
0 - ZLN 152 55.5 23.8 84 100/52 ++
0 - ZLN 169 58.7 20.2 68 160/90 ++
0 - ZLN 164 57.3 21.6 80 124/72 ++
0 - ZLE 159 48.1 19 76 122/70 ++
0 - ZLN 160 60.2 23.4 78 142/80 ++
1 12 TLN 151 41.7 18 74 110/70 ++
0 - ZLE 154 59.8 25.3 72 162/80 ++
0 - ZLE 163 61.9 23.3 72 150/80 R-PT/DP+,L-PT+
- - - 162 63 24 84 150/92 ++
0 - ZLE 156 55.2 22.6 80 112/64 ++
0 - ZLN 168 68 23.8 80 144/76 ++
1 24 TLN 170 88.4 30.8 74 126/78 ++
0 - ZLE 165 46 16.9 72 100/58 ++
0 - ZLN 154 50 21.1 76 116/66 ++
0 - ZLN 171 75.5 26 76 126/70 ++
0 - ZLN 153 40 17.1 74 130/70 ++
1 7 TRA 168 75 26.6 88 110/68 ++
0 - ZLN 156 50 20.5 64 126/70 ++
1 18 TLE 170 67.1 23.2 86 130/70 ++
0 - ZLN 184 70.6 21 74 124/76 ++
0 - ZLN 156 48.3 20.1 76 120/70 ++
0 - ZLN 156 51.6 21.4 78 124/76 ++
1 24 TLN 165 47.2 17.6 84 120/78 ++
0 - ZLN 159 73 28.9 74 148/82 ++
0 - ZLN 175 82 26.8 76 142/90 ++
0 - ZLN 179 72.9 22.8 96 122/68 ++
0 - ZLN 177 66.7 21.4 76 140/80 ++
1 12 TLN 165 53.2 19.5 86 162/80 ++
0 - ZLN 164 57.8 21.6 78 140/82 ++
1 22 TLE 152 57.5 25.1 68 112/58 ++
0 - ZLE 159 56.2 22.2 80 140/86 ++
0 - ZLN 170 65 22.5 80 160/88 ++
0 - ZLE 169 59 20.7 76 130/70 L-PT&DP -,R-PT&DP +
1 3 TLE 174 82 27.1 74 120/90 ++
1 0.5 TLE 154 41.9 17.7 88 104/60 ++
0 - ZLN 160 53.2 20.7 68 116/72 ++
0 - ZLN 145 60.3 28.7 78 110/72 ++
0 - ZLN 172 48 16.2 78 112/68 ++
0 - ZLN 170 71 24.6 80 120/70 ++
1 14 TLN 148 47.1 21.5 74 122/64 ++
0 - ZLN 140 52 26.5 76 112/66 ++
0 - ZLN 154 53 22.3 80 130/76 ++
0 - ZLN 170 59.1 2.04 78 130/80 ++
0 - ZLN 150 56 24.9 92 120/70 ++
0 - ZLN 150 42.7 19 86 90/58 ++
0 - ZLN 164 64.2 23.1 80 140/82 ++
0 - ZLN 155 54 22.5 76 136/74 ++
0 - ZLN 162 45 17.1 74 96/66 ++
0 - ZLN 174 73 24.1 94 134/80 ++
1 6 TLN 159 48.1 19 64 120/74 ++
1 3 TLE 150 55.1 24.5 84 120/62 ++
1 18 TLE 156 40.3 16.6 80 120/76 ++
0 - ZLN 168 82.6 29.3 100 146/86 ++
0 - ZLN 156 59.6 24.6 84 150/74 ++
0 - ZLN 156 54 22.2 88 190/100 ++
0 - ZLE 140 43 21.9 74 130/90 ++
0 - ZLN 168 41.1 14.6 76 118/64 ++
- - - 152 54 23.9 78 110/58 ++
1 12 TLN 158 51 20.4 86 120/80 ++
1 3 TLE 150 45.9 20.4 80 130/80 ++
1 2 TLE 159 49.1 19.4 74 120/64 B/LU+,L;DP-,R:DP+,B/LPTA+
0 - ZLN 174 67 22.1 76 106/58 ++
0 - ZLN 162 46.3 17.6 80 120/80 ++
0 - ZLN 172 75.2 25.4 82 152/88 ++
0 - ZLN 150 34.1 15.2 80 102/60 ++
- - - 172 65 22 74 102/72 ++
- - - 158 53 21.2 76 142/90 ++
1 1 TLE 166 46.8 17 76 102/62 ++
1 0.5 TLE 169 56.9 19.9 80 150/90 ++
0 - ZLN 149 53.2 24 76 142/84 ++
0 - ZLN 157 53 21.5 68 122/68 ++
0 - ZLN 136 27.4 14.8 94 100/54 ++
0 - ZLN 162 63 24 74 130/82 ++
0 - ZLE 162 51.4 19.6 76 90/50 ++
0 - ZLN 163 58.7 22.1 78 126/74 ++
0 - ZLN 147 60.3 27.9 66 112/54 ++
0 - ZLN 171 46.2 15.2 78 140/70 ++
1 16 TLE 148 61.1 27.9 80 150/80 ++
1 24 TAR 148 39 17.8 76 96/52 ++
1 24 TRA 160 38 14.8 84 110/70 ++
0 - ZLN 148 56 25.6 80 120/72 ++
0 - ZLE 156 45.6 18.7 74 130/76 ++
0 - ZLN 162 50 19.1 76 130/72 ++
1 21 TLN 164 57.3 21.3 74 120/100 ++
0 - ZLN 176 77 24.9 88 130/78 ++
0 - ZLN 161 61.3 23.6 84 136/74 ++
0 - ZL 160 65.9 25.7 74 128/68 ++
0 - ZLN 160 51.6 20.2 76 124/72 ++
0 - ZLN 150 39 17.3 78 126/66 ++
0 - ZLN 164 59.9 22.3 82 120/74 ++
0 - ZLN 160 63.8 24.9 68 140/90 ++
0 - ZLN 159 48 19 84 140/86 ++
1 5 TLE 146 44.6 20.9 72 120/70 L-PT&DP+
1 6 TLN 154 45 19 88 140/84 DP+
0 - ZLN 160 50.8 23.4 86 110/70 PT,DPB/L -,B/LPOP,R-F,B/L:U +
0 - ZLN 156 78 32.1 84 120/72 ++
0 - ZLN 150 56 24.9 72 110/64 ++
0 - ZLN 169 57.4 20.1 80 120/80 ++
1 8 TLN 170 54.4 18.8 76 128/72 ++
0 - ZLE 164 37.6 14 78 90/62 ++
0 - ZLN 165 60 22 74 130/70 ++
0 - ZLN 157 54.8 22.2 90 126/74 ++
1 12 TLN 142 39.8 19.7 80 122/70 ++
1 20 TLN 170 76.2 26.4 84 132/74 ++
0 - ZLN 153 46.9 20 78 116/58 ++
0 - ZLN 148 57.5 26.3 92 124/68 ++
0 - ZLN 150 52.9 23.5 68 130/80 ++
0 - ZLE 174 59 19.5 74 118/56 ++
0 - ZLN 176 65.9 21.3 80 118/60 ++
0 - ZLE 152 46.5 20.1 76 124/66 ++
0 - ZLN 140 61.7 31.5 78 156/76 ++
0 - ZLN 148 39.5 18 80 100/58 ++
0 - ZLN 168 55.3 19.6 72 120/76 ++
0 - ZLN 170 64 22.1 78 130/66 ++
0 - ZLN 167 65.7 23.6 80 128/64 ++
0 - ZLN 153 46 19.7 74 96/54 ++
1 36 TLN 155 44.6 18.4 80 110/68 ++
0 - ZLN 150 51.7 23 76 110/78 ++
0 - ZLN 166 61.2 22.2 86 130/88 ++
0 - ZLN 166 101 36.4 72 120/80 ++
0 - ZLN 164 46.4 17.3 80 90/60 ++
1 4 TLN 160 70.9 27.7 72 110/60 ++
1 48 TLE 159 54 21.4 76 100/58 ++
0 - ZLN 176 82 26.2 74 130/72 ++
0 - ZLN 167 58 20.9 76 170/100 ++
1 24 TLN 157 66.3 26.9 84 124/72 ++
0 - ZLN 170 70.7 24.5 80 120/70 ++
0 - ZLN 145 42.7 20.3 66 100/52 ++
0 - ZLN 155 65.8 27.4 72 110/58 ++
0 - ZLN 169 58 20.3 76 130/70 ++
0 - ZLN 170 64 22.1 78 116/68 ++
0 - ZLN 144 58.8 28.4 70 110/70 ++
0 - ZLN 155 52.2 21.7 78 110/60 ++
0 - ZLN 157 64.6 26.2 88 100/52 ++
0 - ZLN 164 55.1 20.5 80 118/68 ++
0 - ZLN 148 42.8 19.5 70 118/72 ++
0 - ZLN 163 57.3 21.7 64 122/72 ++
1 7 TLN 172 86 29.1 86 130/80 ++
0 - ZLN 175 49.8 16.3 76 134/80 ++
0 - ZLN 160 59.2 23.1 88 100/64 ++
0 - ZLN 165 68.6 25.2 84 130/80 ++
0 - ZLN 170 69.4 24 78 140/72 ++
0 - ZLN 157 56 22.7 100 116/62 ++
1 12 TLE 172 63 21.3 76 130/78 ++
0 - ZLN 154 60.6 25.6 90 118/58 ++
0 - ZLN 154 53.2 27.5 68 114/74 ++
0 - ZLN 152 60.3 26.1 76 110/70 ++
1 48 TLN 155 57 23.7 84 110/66 ++
1 8 TLN 164 48.8 18.1 88 116/70 ++
0 - ZLN 170 49.1 17 84 90/54 ++
1 18 TLN 176 82.5 26.6 72 160/100 ++
0 - ZLN 167 58.6 21 78 110/58 ++
0 - ZLE 155 61.8 25.7 76 128/70 ++
1 42 TAR 168 61.5 21.8 76 128/80 ++
1 3 TLE 164 53 19.7 96 130/76 ++
0 - ZLN 166 67.9 24.6 84 130/74 ++
1 84 TLE 152 54.6 23.6 96 124/70 ++
1 12 TLE 154 67.7 28.5 84 132/80 ++
0 - ZLN 153 55 23.5 76 140/80 ++
0 - ZLN 165 62 22.8 100 108/58 ++
0 - ZLN 156 46.1 18.9 92 116/54 ++
1 26 TLN 154 52 21.9 80 108/62 ++
0 - ZLN 159 53.4 21.1 76 124/74 ++
0 - ZLE 149 46.4 20.9 76 120/72 ++
ABI Re-R ABI Re-L ABPI Ex-R ABPI Ex-L TP-R TP-L HB T.CHOLESTEROLTG
1.08 1 0.91 1.08  -  - 12.2 281 494
0.96 0.98 1.05 1.07  -  - 12.8 N/A N/A
0.91 0.91 0.91 0.9  -  - 12 N/A N/A
1.04 1 1 1  -  - 12 190 108
1.2 1.18 1.06 1.04 100 90 13.3 N/A N/A
1.11 1.12 0.97 1.01 141 140 14.9 115 130
1.27 1.31 1.14 1.11 134 164 14.3 204 232
0.98 0.96 1.03 0.94  -  - 13.9 N/A N/A
1.1 1.15 1.2 1.32 118 72 13.1 N/A N/A
1.08 1.2 1.21 1.14 118 120 14.3 165 94
1.03 1 0.98 0.85  -  - 9.2 N/A N/A
0.9 1.33 0.9 1.22 80 40 12.2 N/A N/A
1.2 1.13 0.94 0.88 110 94 12.6 188 86
1 1 1.11 0.88  -  - 8.1 N/A N/A
1.42 0.32 1 0.3 100 0 14.6 117 148
1.11 1.11 1 1  -  - 9.9 N/A N/A
1 1.14 1.14 1 70 88 12.9 270 231
1.23 1.14 1.06 1.14 80 84 9.1 N/A N/A
0.92 0.95 0.87 0.87  -  - 13.9 N/A N/A
1.12 1 1.09 0.96  -  - 12.7 162 139
1.01 0.91 0.95 0.88  -  - 13.2 N/A N/A
1.12 1.1 1.06 1.11  -  - 13.8 127 94
1.07 1.03 1.02 1  -  - 12 150 88
1 0.94 0.98 0.95  -  - 8.1 162 160
1.03 1.09 1.07 1.07  -  - 12.3 N/A N/A
1 0.95 0.98 0.9  -  - 12.5 N/A N/A
0.98 0.95 0.93 0.93  -  - 14.4 N/A N/A
1.03 1.12 1 1.02  -  - 11.4 236 218
1 1.08 0.98 0.96  -  - 9.4 N/A N/A
0.92 1 0.9 0.96  -  - 14 N/A N/A
1 1 0.96 0.94  -  - 14.8 N/A N/A
1.06 1.1 0.99 0.98  -  - 15.2 105 266
1.07 1.09 1 1.04  -  - 13.4 87 94
1.05 1.02 1.03 1  -  - 10.1 N/A N/A
0.94 1.09 0.95 0.95  -  - 13.5 N/A N/A
1.08 1.1 1 1.02  -  - 12.6 210 247
0.91 1.03 0.88 0.95  -  - 11.1 N/A N/A
1 1.07 0.99 1.03  -  - 13 N/A N/A
1.02 1.04 1 0.96  -  - 9 N/A N/A
1.04 1.02 0.97 0.98  -  - 9.3 136 161
1 1.01 0.96 0.95  -  - 12.4 134 124
0.94 0.96 0.91 0.92 - - 10.7 N/A N/A
1.16 1.96 1.1 1.8 80 70 9.9 N/A N/A
0.95 1.11 0.92 1.05 - - 14.6 N/A N/A
0.96 1.1 0.91 0.97  -  - 5.7 N/A N/A
1.09 1.07 1.01 1.02  -  - 10.6 N/A N/A
1.02 1 1.02 0.97 - - 13.2 N/A N/A
1.06 1.08 1.01 1.02 - - 14.5 N/A N/A
0.93 0.95 0.9 0.93  - - 9.4 N/A N/A
1.02 1.08 0.97 0.99  -  - 9.3 150 104
1.01 1.08 0.96 1 - - 14.1 167 208
1.07 0.94 1.06 0.92  -  - 13.7 N/A N/A
1.07 1.1 1.08 1.07  -  - 11.6 N/A N/A
1.05 1.03 1 1.04  -  - 10.6 N/A N/A
1.07 1.09 1.06 1  -  - 14.5 N/A N/A
0.93 0.84 0.84 0.81 - - 11.4 N/A N/A
1 1.22 1.2 1.18 90 110 9.2 N/A N/A
1.14 1.08 1.25 1.17 108 112 14.2 173 119
1.15 1.09 1.03 1.07 - - 11.5 N/A N/A
0.89 0.86 0.89 0.95  -  - 12.6 N/A N/A
1.07 1.06 1.04 1.04  -  - 11.5 166 76
1.07 1.08 1.09 1.03  -  - 10.9 182 129
0.95 0.97 1 1.05  -  - 11.1 120 119
1.03 1.03 1.13 1.06  -  - 9.5 N/A N/A
0.97 0.92 0.94 0.92  -  - 12.1 N/A N/A
1.05 0.99 0.98 1  -  - 14.1 N/A N/A
1.07 0.97 1.05 0.83  -  - 12.5 192 167
0.91 0.91 1.06 1  -  - 11.3 162 128
1.15 1.07 1.08 1.2 100 98 11.6 153 236
1.14 1.31 1.04 1.07 104 114 12.2 N/A N/A
1 0.93 1.11 1.01  -  - 11.9 N/A N/A
1.06 0.98 0.86 0.81  -  - 13 N/A N/A
1.12 1.25 1.11 1.09 108 120 14.7 151 128
1.01 1.05 1.01 1.03  -  - 11.3 136 77
1.07 1.09 1.02 1.1  -  - 13.1 N/A N/A
1.14 1.14 1.12 1.07 104 102 15.3 181 283
1.03 1.08 0.98 0.97 - - 12.8 N/A N/A
1.02 1.03 1.12 1.04 100 88 13.6 N/A N/A
1.05 1.08 1.03 1.05 - - 10.1 N/A N/A
1 1.08 0.92 0.98  -  - 9 118 248
1.06 1.07 1 1.01  -  - 16.5 N/A N/A
1.07 1.07 1.03 1.03  -  - 11.7 160 133
1.14 1.07 1.04 1.03 88 102 14.7 N/A N/A
1.07 1.03 1.03 1.05  -  - 13.8 112 58
1.02 1 1.01 0.98  -  - 12.2 N/A N/A
1.02 0.98 1.03 1.06  -  - 13.5 136 94
1.06 1.02 0.93 1  -  - 11.9 N/A N/A
1.09 0.98 0.98 0.92  -  - 11.4 179 120
0.96 0.91 0.94 0.91  -  - 9.4 N/A N/A
1.04 1 1.05 0.98  -  - 11.7 N/A N/A
0.92 0.92 0.92 0.91  -  - 10.2 N/A N/A
0.99 0.93 0.91 1  -  - 11.4 120 426
1.1 1.08 1 1.04  -  - 8.7 170 134
1.07 1 1.02 0.98  -  - 9.9 N/A N/A
1.21 1.16 1.19 1.1 110 102 11.5 139 482
0.98 1.02 0.91 0.91  -  - 10.6 N/A N/A
1.02 1 1.01 0.98  -  - 15.6 N/A N/A
1.17 1.03 1.02 1.03  -  - 9.7 N/A N/A
1.06 1.05 1.14 0.97  -  - 12.5 N/A N/A
0.98 1.02 0.98 0.98  -  - 15.5 158 158
1.01 1.07 1.13 0.99  -  - 15.7 113 154
1.04 1 0.97 1.01  -  - 11.8 N/A N/A
0.97 0.93 1.08 1.09  -  - 10.5 N/A N/A
1.18 1.13 1.07 1.1 98 114 13.6 N/A N/A
1.06 1.02 0.98 1  -  - 11.4 203 237
0.94 0.95 1.15 1.12  -  - 13.2 171 457
0.91 0.91 0.93 0.91  -  - 11.8 N/A N/A
1 1.13 1.02 1.1  -  - 14.6 N/A N/A
1.15 1.16 1.18 1.05 88 96 12.8 146 201
1.04 1.15 1.05 1.15 118 104 15.7 N/A N/A
1 0.98 1.03 1.02  -  - 11.5 N/A N/A
1.09 1.15 1.12 1.15  -  - 13.5 N/A N/A
0.89 0.87 0.88 0.9  -  - 12.1 N/A N/A
1.08 1.1 1.02 1  -  - 12.6 N/A N/A
0.97 0.93 1.05 1.02  -  - 12.7 N/A N/A
1.01 1.03 1 1.03  -  - 11.7 N/A N/A
1.01 1 1.16 1.13  -  - 12.9 N/A N/A
0.87 1.01 0.97 0.97  -  - 10 N/A N/A
0.98 0.98 0.95 0.93  -  - 11.4 N/A N/A
1 1.01 0.91 1  -  - 10.6 N/A N/A
1.09 1 1 0.98  -  - 10.6 N/A N/A
1.05 1 1.02 1.1  -  - 15.2 105 266
1.13 1.04 1.13 1  -  - 15.8 185 165
1.01 1.02 0.97 1.02  -  - 14.8 N/A N/A
1 0.98 1.04 0.98  -  - 10.2 138 167
1 1.03 1.04 1.07  -  - 15.2 137 120
1.02 0.98 1.07 1.09  -  - 9.8 N/A N/A
1.02 1 1 1.08  -  - 11.9 N/A N/A
1.01 1 0.98 0.93  -  - 8 N/A N/A
1.09 1.09 1.02 1.02  -  - 12 102 255
1.03 0.94 1.03 1.02  -  - 14.9 N/A N/A
1.13 1.15 1.04 1.07  -  - 6.8 124 181
1.02 1.08 1 0.98  -  - 14.8 N/A N/A
1 1 1.02 1  -  - 14.9 167 168
1 0.98 1.03 1.08  -  - 15 N/A N/A
0.98 0.94 1.08 0.96  -  - 15.9 N/A N/A
1.08 1.11 1.07 1.08  -  - 13.5 N/A N/A
0.94 0.9 0.98 0.97  -  - 14.8 N/A N/A
0.97 0.94 0.92 0.92  -  - 13.2 N/A N/A
0.91 0.95 0.92 0.92  -  - 10.2 N/A N/A
0.92 0.93 0.91 0.93  -  - 16 N/A N/A
1.03 1.02 0.92 0.92  -  - 10.7 116 92
1.01 1.04 0.93 0.95  -  - 12 N/A N/A
0.92 0.93 0.93 0.95  -  - 13.1 N/A N/A
0.96 1.04 0.96 0.98  -  - 11.5 N/A N/A
1.02 1.04 0.98 1.02  -  - 15.1 135 56
0.95 0.97 0.95 0.83  -  - 13.5 N/A N/A
0.95 1.03 1.08 1.1  -  - 15.3 N/A N/A
0.95 0.98 0.98 0.93  -  - 14.7 N/A N/A
0.98 1.03 1.1 0.96  -  - 16.8 N/A N/A
1.02 1.08 1.06 1.04  -  - 14.3 109 194
1.01 1 0.97 0.94  -  - 13.1 201 178
1.02 0.98 0.95 0.92  -  - 12.3 N/A N/A
0.98 0.93 0.94 0.92  -  - 11.1 101 88
0.89 0.87 0.86 0.83  -  - 14 N/A N/A
1.02 1 0.98 1.05  -  - 13.9 N/A N/A
1.03 1.05 0.97 0.98  -  - 14 N/A N/A
0.93 0.94 1.03 1.01  -  - 15.3 N/A N/A
0.97 0.92 0.97 0.92  -  - 6.4 N/A N/A
0.97 1 0.94 0.95  -  - 13.4 N/A N/A
1.03 1.02 1.01 0.99  -  - 14.6 N/A N/A
1.09 1.07 0.98 0.98  -  - 13.4 N/A N/A
1.01 0.99 1.01 0.99  -  - 13.3 145 176
0.97 1.1 1.07 1.13  -  - 14.5 202 233
1.09 1.07 1.07 1.08  -  - 12 N/A N/A
0.94 0.92 0.94 0.9  -  - 12.3 N/A N/A
1.08 1.03 1.1 1.09  -  - 15.3 N/A N/A
1.13 1.2 1.21 1.15 94 120 12.5 348 1385
0.99 1.03 0.99 0.99  -  - 12 N/A N/A
1.06 1.12 0.99 0.97  -  - 13.8 144 80
1.06 1.07 1.01 0.94  -  - 15.6 N/A N/A
0.98 1.08 0.95 0.93  -  - 10.1 N/A N/A
1 1.02 0.99 0.97  -  - 14.3 N/A N/A
1.01 0.96 1.06 1.01  -  - 13.4 N/A N/A
0.95 0.93 0.92 0.94  -  - 13.8 162 106
0.99 0.96 0.92 0.93  -  - 13.5 N/A N/A
0.93 0.99 0.9 0.96  -  - 12.1 N/A N/A
1.04 1.12 0.99 1.03  -  - 13 N/A N/A
0.92 0.9 0.89 0.9  -  - 12.3 N/A N/A
1.06 1.1 0.99 1.01  -  - 12.3 160 123
1.06 1.12 0.96 0.94  -  - 12.4 N/A N/A
0.95 0.95 0.92 0.91  -  - 8.9 N/A N/A
1.07 1.14 1.03 1.04  -  - 11 230 865
0.92 0.98 0.97 0.98  -  - 15 174 102
1.06 0.94 1 1.04  -  - 14.2 N/A N/A
0.87 0.89 0.95 1  -  - 12.7 N/A N/A
0.94 0.93 0.96 0.96  -  - 12.2 N/A N/A
0.91 0.9 0.9 0.96  -  - 8.5 222 89
0.92 0.95 1.07 0.91  -  - 15.9 136 143
1.06 1.14 1.1 1.05  -  - 13.2 N/A N/A
1.02 1 1.01 1.04  -  - 15.1 194 263
1.25 1.15 1.12 1.1 80 90 10.9 176 87
0.98 1.04 0.96 0.98  -  - 7.8 N/A N/A
1.06 1.08 1.09 1.09  -  - 13.8 N/A N/A
0.91 0.94 0.95 0.96  -  - 14 N/A N/A
0.92 0.91 0.89 0.87  -  - 9.4 N/A N/A
0.98 0.97 0.98 0.95  -  - 14.5 171 97
1.01 1.03 1.02 1  -  - 15.6 N/A N/A
1.03 1 0.93 0.95  -  - 9.7 N/A N/A
0.9 0.92 0.98 0.92  -  - 12.4 N/A N/A
1.01 1 0.99 0.99  -  - 12.5 N/A N/A
0.99 0.95 0.87 0.91  -  - 15.5 N/A N/A
1.1 0.98 0.96 0.94  -  - 11 N/A N/A
0.98 0.94 0.92 0.9  -  - 12.6 N/A N/A
1.07 1.06 1.08 1.07  -  - 17.4 N/A N/A
1.02 0.92 0.91 0.92  -  - 11.1 N/A N/A
1.01 0.99 0.95 0.93  -  - 13.6 N/A N/A
1.01 1.02 0.98 0.99  -  - 13 N/A N/A
1.06 1.05 1.01 0.99  -  - 16.4 N/A N/A
0.93 0.94 0.97 0.99  -  - 10.4 N/A N/A
1.21 1.25 1.21 1.29 84 72 12.3 N/A N/A
1 0.98 0.98 0.95  -  - 9.8 N/A N/A
0.91 0.97 0.91 0.92  -  - 13.5 N/A N/A
1.02 0.95 0.98 1.01  -  - 10.7 N/A N/A
0.91 0.91 1 0.98  -  - 7.9 N/A N/A
0.97 0.97 0.94 0.93  -  - 15.5 218 373
0.99 1.01 0.97 1  -  - 10.6 164 94
0.9 0.98 0.98 0.96  -  - 11.9 156 60
1.01 0.99 1.02 1.01  -  - 17 141 81
0.9 0.93 0.98 0.97  -  - 10.5 N/A N/A
1.14 0.92 0.95 0.97  -  - 10.3 N/A N/A
1.01 1 0.99 0.99  -  - 13.1 N/A N/A
0.9 0.91 0.94 0.91  -  - 10.8 N/A N/A
1.02 0.95 1.05 1.02  -  - 11 N/A N/A
0.96 0.99 0.94 0.96  -  - 12.4 N/A N/A
1.02 1 0.98 1  -  - 12.6 N/A N/A
1.02 0.98 0.92 0.96  -  - 13.3 N/A N/A
1.07 1.08 0.99 1.02  -  - 14.1 N/A N/A
1.11 1.19 1.07 1.09 100 110 11.6 N/A N/A
0.96 1 0.94 0.98  -  - 10.8 N/A N/A
1 1.1 0.97 1  -  - 13.8 N/A N/A
1.13 1.11 1.12 1.05  -  - 13.5 N/A N/A
1.09 1.04 1.01 1.02  -  - 14.3 211 100
0.94 0.97 0.98 0.96  -  - 14.6 147 76
0.97 0.92 0.94 0.96  -  - 13.3 229 242
1.02 1.03 0.98 1  -  - 12.1 161 341
1.03 1.01 1.06 1.09  -  - 11.7 N/A N/A
1.2 1.17 1.08 1.08 100 108 13.2 N/A N/A
1.02 0.98 0.92 0.94  -  - 14 N/A N/A
0.96 1.02 0.94 0.96  -  - 12.2 N/A N/A
0.91 0.93 0.9 0.92  -  - 12.1 146 307
1.09 1.11 1.06 1.09  -  - 12.6 N/A N/A
1.07 1.08 1.07 1.11  -  - 12.5 N/A N/A
1.13 1.06 1.04 0.94  -  - 15.3 N/A N/A
0.87 0.89 0.91 0.87  -  - 12.4 134 124
0.94 0.94 0.93 0.93  -  - 13.6 N/A N/A
0.85 0.87 0.91 0.89  -  - 14.2 N/A N/A
1.06 1.08 1.04 1.06  -  - 14.2 N/A N/A
0.9 0.91 0.91 0.9  -  - 12.6 N/A N/A
0.99 1.03 1.07 1.08  -  - 12.6 N/A N/A
1.11 1.13 1.21 1.1 100 90 14.3 N/A N/A
1.02 1.04 1 1.02  -  - 10.5 N/A N/A
1.03 0.95 1.02 1  -  - 6.6 N/A N/A
1.07 1.05 1.06 1.05  -  - 16.7 N/A N/A
1 1.05 0.98 0.98  -  - 13.1 N/A N/A
1.13 1.05 1.12 1.03  -  - 14.5 N/A N/A
0.98 0.97 1.03 0.98  -  - 12.7 N/A N/A
1.05 0.98 0.98 0.98  -  - 11.3 N/A N/A
0.94 0.97 0.94 0.92  -  - 14.2 N/A N/A
1.03 1.02 0.99 0.98  -  - 12.1 N/A N/A
1.02 0.98 1.03 1.02  -  - 9.8 N/A N/A
1 0.97 1.1 1.09  -  - 12 156 102
1.22 1.2 1.09 1.22 190 150 12.8 201 579
1.06 1.27 1.17 1.21 140 124 14.6 192 280
1.02 1.08 1 1.04  -  - 15 N/A N/A
1.01 1.04 1.01 1  -  - 12.4 N/A N/A
1.01 1.02 0.99 0.97  -  - 15 N/A N/A
1.01 1.07 0.96 0.99  -  - 13.6 N/A N/A
0.91 0.95 1.03 1  -  - 11.2 N/A N/A
0.91 0.93 0.97 0.94  -  - 11.3 N/A N/A
1.05 1.06 1.01 1  -  - 14.2 151 170
0.92 0.85 0.98 0.77  -  - 13 N/A N/A
1.02 0.98 1.11 1.03  -  - 13.8 N/A N/A
1.04 1.04 0.91 1.02  -  - 11.4 N/A N/A
1.09 1.12 0.98 1.07  -  - 10.5 99 154
0.98 1.02 0.93 1.02  -  - 12.1 N/A N/A
0.96 0.95 1.03 0.95  -  - 6.6 N/A N/A
1.08 1 0.95 1.11  -  - 6.5 257 1163
0.98 1.07 0.92 0.95  -  - 12.4 N/A N/A
0.93 0.91 1 0.97  -  - 12.1 175 118
1.15 1.08 1.02 0.97  -  - 14.1 N/A N/A
1.08 1.08 0.95 0.97  -  - 11.2 N/A N/A
0.98 1.03 1.07 1  -  - 10.1 N/A N/A
1.22 1.11 1.1 1.08 110 100 11.8 N/A N/A
1.06 0.99 1.04 1.01  -  - 12.4 N/A N/A
1.07 1.1 1.11 1.14  -  - 13.6 N/A N/A
1.12 1.04 1.2 1.16 90 80 11.9 N/A N/A
1.09 1.03 1.06 1.03  -  - 15.1 131 N/A
1.03 1.07 1.11 1.07  -  - 14.2 N/A N/A
1.03 1.07 1.07 1.02  -  - 12.8 N/A N/A
0.92 0.9 0.95 0.93  -  - 12.9 N/A N/A
0.88 0.86 0.96 0.88  -  - 11.1 N/A N/A
0.93 1.07 0.95 0.96  -  - 10.7 N/A N/A
1.11 1.03 1.03 0.99  -  - 13.4 N/A N/A
1.03 0.98 1.02 0.98  -  - 12.1 198 104
0.92 0.95 0.94 0.92  -  - 12.3 N/A N/A
1.02 0.98 0.98 0.95  -  - 11.8 N/A N/A
0.92 1.03 0.92 0.91  -  - 11.2 N/A N/A
0.95 0.91 0.94 0.97  -  - 14.1 N/A N/A
0.83 0.85 0.9 0.8  -  - 8.5 200 110
1.13 1.13 1.07 1.02  -  - 14.7 N/A N/A
0.91 0.91 0.94 0.98  -  - 9.4 N/A N/A
1.18 1.24 1.13 1.19 84 96 11.1 N/A N/A
0.98 1 1.02 0.98  -   - 11.6 N/A N/A
0.98 1.07 1 0.96  -  - 12.7 N/A N/A
1 0.98 1.01 0.98  -  - 11.3 112 212
0.98 1.05 0.81 0.96  -  - 10 N/A N/A
0.6 0.61 0.64 0.63  -  - 12.8 N/A N/A
1.13 1.14 1.09 1.11  -  - 12.9 260 1100
1.01 1.06 0.96 1.01  -  - 11 N/A N/A
0.96 0.99 0.97 0.9  -  - 9.5 N/A N/A
1.23 1.11 1.21 1.05 82 90 5.7 88 102
1.02 1 0.98 0.99  -  - 12.2 N/A N/A
1.01 1.04 0.97 0.98  -  - 12.6 184 100
1.05 0.98 1.01 0.96  -  - 12.8 N/A N/A
0.94 0.92 0.92 0.94  -  - 16.2 N/A N/A
1.05 1.06 1.05 0.97  -  - 12.7 N/A N/A
1.1 1.14 1.14 1.04  -  - 12.5 192 82
1.07 1.05 1.03 1.01  -  - 14.8 N/A N/A
1.03 1.06 1.03 1.06  -  - 11.2 144 70
0.96 0.92 1.01 0.95  -  - 14.3 N/A N/A
0.96 0.9 1 0.93  -  - 13.5 N/A N/A
1.03 0.91 1.01 0.91  -  - 14.3 N/A N/A
1.06 1.07 1.06 1.06  -  - 13.3 N/A N/A
1.04 1.07 1.19 1.06 100 114 14.8 N/A N/A
1.07 1 0.98 0.93  -  - 13.3 N/A N/A
1.01 1.04 1 0.98  -  - 11.8 N/A N/A
0.88 0.9 0.96 0.94  -  - 14.5 184 102
1.08 1.13 1.15 1.07  -  - 12.8 N/A N/A
1.27 1.32 1.08 1.19 104 90 13.4 N/A N/A
1.05 1.01 1.04 1.07  -  - 10.9 N/A N/A
1.08 1.01 0.95 0.79  -  - 11.3 N/A N/A
1.25 1.24 1.13 1.07 100 90 11.3 N/A N/A
0.27 0.36 0.3 0.3  -  - 14 240 108
1 1.08 1.08 1.07  -  - 13.8 N/A N/A
1 1.09 11.01 1.05  -  - 10.2 N/A N/A
1.1 1 1.14 1.12  -  - 14.7 N/A N/A
1.06 1.08 1.09 1.12  -  - 14.7 N/A N/A
1 1 1.1 1  -  - 11.6 N/A N/A
0.98 1.08 1.13 1.08  -  - 12.1 N/A N/A
0.96 1.01 1.27 1.23 124 110 13 N/A N/A
1.01 1.06 0.9 0.93  -  - 7.5 N/A N/A
0.98 1.01 0.91 0.94  -  - 15.8 N/A N/A
0.94 0.96 1.07 0.98  -  - 12.7 N/A N/A
0.98 1.08 1.06 1.03  -  - 13.9 N/A N/A
1.01 1 0.98 0.92  -  - 12.5 N/A N/A
0.98 1.05 1.01 1.1  -  - 12.7 N/A N/A
1.1 1.03 0.93 0.91  -  - 13.8 N/A N/A
1.03 1.04 0.94 0.98  -  - 11.3 N/A N/A
1.03 1.02 0.95 0.92  -  - 12.2 N/A N/A
1.04 1.06 1.09 0.96  -  - 14 N/A N/A
1.08 1.1 1.03 1.04  -  - 13.8 184 92
1.07 1.03 0.97 0.92  -  - N/A N/A N/A
1.01 1.04 1.04 1.04  -  - 14.7 N/A N/A
1.08 1.12 1.08 1.06  -  - 12.6 N/A N/A
1.09 1.07 1.03 0.98  -  - 10.2 N/A N/A
0.96 0.98 1.01 1.03  -  - 10.4 N/A N/A
1.06 1.04 1.01 1.03  -  - 14.5 N/A N/A
1.14 1.1 1.12 1.03  -  - 14.6 N/A N/A
1.2 1.31 1.16 1.18 90 100 11.5 N/A N/A
1.1 1.05 1.07 1.01  -  - 12.7 126 87
1.04 1 0.92 1  -  - 16.2 N/A N/A
1.09 1.07 1.07 1.02  -  - 13.3 185 244
0.94 0.92 0.92 0.95  -  - 9.9 N/A N/A
1.03 1.06 1.01 1.09  -  - 11.6 N/A N/A
0.91 0.98 0.95 1.03  -  - 16.7 N/A N/A
1.12 1.1 1.03 1.05  -  - 11.6 N/A N/A
1.09 1.07 1.03 1.05  -  - 11.3 N/A N/A
1.07 1 0.96 0.95  -  - 13.3 142 169
1.12 1.1 1.11 1  -  - 11.8 N/A N/A
1.05 1.03 1.05 1.09  -  - 12.6 N/A N/A
1.07 1.01 1.05 1.05  -  - 12.3 N/A N/A
0.98 1.08 0.98 0.94  -  - 13.4 N/A N/A
1 1.01 1.03 1.06  -  - 16.2 N/A N/A
0.98 1.03 1.05 1.06  -  - 11.1 N/A N/A
1.04 1.04 1.06 1.03  -  - 12.6 N/A N/A
1.03 1 0.96 0.98  -  - 16.1 187 67
1.01 0.95 0.95 0.94  -  - 13.6 N/A N/A
0.94 1 0.95 0.93  -  - 11.6 149 99
1.05 1.06 1 1  -  - 11.7 205 295
1.04 0.99 0.99 0.97  -  - 14.4 N/A N/A
1.02 1 1.05 1  -  - 13.6 N/A N/A
1.08 1.09 1 1.08  -  - 12.5 N/A N/A
1 1.03 1.05 1.05  -  - 13.3 N/A N/A
1.02 0.96 1 1.02  -  - 13.1 N/A N/A
1.04 1.04 0.97 1.02  -  - 12.5 N/A N/A
1.09 1.1 1.07 1.07  -  - 11.5 N/A N/A
1 1 0.95 0.97  -  - 10 N/A N/A
1.07 1.09 1 1.04  -  - 14.3 259 56
1.07 1.06 1.07 1.04  -  - 15.7 197 155
1.07 1.05 1.06 1.04  -  - 14.3 N/A N/A
1.05 0.98 0.98 0.95  -  - 13.3 N/A N/A
0.98 1.06 0.93 0.96  -  - 12.9 138 322
1.03 1.08 1 1  -  - 11.8 N/A N/A
1.02 1.03 1.03 0.99  -  - 15.7 226 122
0.98 0.95 1.02 1  -  - 13.8 N/A N/A
1.02 1.03 1.03 0.94  -  - 12.2 N/A N/A
1.03 1.04 0.96 0.99  -  - 13.4 N/A N/A
0.94 1.09 0.91 1  -  - 10 98 55
0.93 0.92 0.92 0.9  -  - 10.7 N/A N/A
1.04 1.07 0.98 0.93  -  - 9.2 N/A N/A
0.97 1.03 0.97 0.94  -  - 11.6 146 53
1.07 1.03 1.06 1.02  -  - 11.1 N/A N/A
HDL LDL CD4 ALBUMIN PAOD?
56 153 921 3.8 0
N/A N/A 1096 2.8 0
N/A N/A 369 4.8 0
50 128 260 3.3 0
N/A N/A 359 4.2 1
23 72 511 4.3 0
32 139 686 4.2 0
N/A N/A 241 3.9 0
N/A N/A 468 3.4 0
51 104 502 4.6 0
N/A N/A 281 4.3 1
N/A N/A 544 N/A 1
53 133 98 3.9 1
N/A N/A 187 2.4 1
26 57 280 4.3 1
N/A N/A 315 2.9 0
61 173 203 4.8 0
N/A N/A 398 3.4 0
N/A N/A 426 3.9 1
17 103 493 4.9 0
N/A N/A 579 5 1
33 94 448 4.2 0
42 108 202 3.5 0
29 107 530 3.3 0
N/A N/A 420 4.1 0
N/A N/A 166 3.9 0
N/A N/A 643 4.2 0
70 141 465 4.5 0
N/A N/A 170 3.4 0
N/A N/A 155 4.4 0
N/A N/A 499 5.1 0
28 39 345 4.3 0
19 54 315 3.7 0
N/A N/A 295 3.4 0
N/A N/A 1179 3.7 0
40 151 306 N/A 0
N/A N/A 198 4.4 1
N/A N/A 194 3.7 0
N/A N/A 127 2.8 0
22 94 236 3.9 0
33 81 670 4 0
N/A N/A 73 3.9 0
N/A N/A 315 2.9 0
N/A N/A 57 4.5 0
N/A N/A 231 2.1 0
N/A N/A 206 3.2 0
N/A N/A 675 N/A 0
N/A N/A 430 4.8 0
N/A N/A 484 4.3 0
26 117 317 2.6 0
41 99 409 2.8 0
N/A N/A 339 4.4 0
N/A N/A 503 4 0
N/A N/A 268 N/A 0
N/A N/A 287 5.1 0
N/A N/A 534 N/A 1
N/A N/A 381 2.6 0
38 103 452 4.8 0
N/A N/A 297 4.5 0
N/A N/A 222 3.8 1
41 96 484 5 0
59 96 114 3.7 0
29 77 527 3.4 0
N/A N/A 271 3.7 0
N/A N/A 299 3.2 0
N/A N/A 204 4.7 0
35 143 278 4.5 1
31 123 330 4.1 0
34 74 698 3.4 0
N/A N/A 465 3.9 0
N/A N/A 206 4.6 0
N/A N/A 349 3.5 1
27 93 528 4.9 0
43 71 177 N/A 0
N/A N/A 164 3.4 0
31 111 257 4.8 0
N/A 41 317 4.7 0
N/A N/A 454 3.1 0
N/A N/A 116 4.4 0
12 101 314 2 0
N/A N/A 190 3.3 0
30 100 15 3.8 0
N/A N/A 275 4.1 0
31 72 333 4.4 0
N/A N/A 965 4.9 0
38 108 36 4.3 0
N/A N/A 639 3.3 0
43 115 344 4.1 0
N/A N/A 170 3.4 0
N/A N/A 367 3.6 0
N/A N/A 1002 N/A 0
20 57 170 4.1 0
39 113 66 1.8 0
N/A N/A 120 2.7 0
26 50 488 4.5 0
N/A N/A 185 3.5 0
N/A N/A 136 3 0
N/A N/A 112 2.9 0
N/A N/A 74 3 0
27 115 325 4.5 0
28 63 1055 4.2 0
N/A N/A 543 3.8 0
N/A N/A 175 4.3 0
N/A N/A 139 4.2 0
41 142 1129 4.7 0
23 83 398 4.8 0
N/A N/A 140 3.7 0
N/A N/A 388 4.3 0
27 87 673 4 0
N/A N/A 611 3.6 0
N/A N/A 710 4 0
N/A N/A 353 3.7 0
N/A N/A 610 3.7 1
N/A N/A 592 3 0
N/A N/A 468 4.7 0
N/A N/A 449 4.2 0
N/A N/A 248 3.7 0
N/A N/A 383 4.1 1
N/A N/A 804 4 0
N/A N/A 688 3.5 0
N/A N/A 688 3.5 0
28 39 345 4.3 0
49 110 582 4.9 0
N/A N/A 605 4.1 0
31 86 474 4.6 0
28 95 874 4.9 0
N/A N/A 148 3.3 0
N/A N/A 639 3.3 0
N/A N/A 662 3.2 0
30 43 215 2.9 0
N/A N/A 323 N/A 0
25 66 164 3.4 0
N/A N/A 315 4.6 0
31 92 446 4.5 0
N/A N/A 204 4.2 0
N/A N/A 636 3.8 0
N/A N/A 154 3.5 0
N/A N/A 757 4 0
N/A N/A 734 4.3 0
N/A N/A 262 4.5 0
N/A N/A 776 4.5 0
31 54 406 3.6 0
N/A N/A 321 4 0
N/A N/A 337 3.8 0
N/A N/A 626 N/A 0
49 74 377 5.2 0
N/A N/A 210 4.8 1
N/A N/A 684 N/A 0
N/A N/A 840 N/A 0
N/A N/A 422 4 0
30 55 144 4.1 0
47 128 537 4.8 0
N/A N/A 498 3.5 0
28 58 378 4.3 0
N/A N/A 710 4.3 1
N/A N/A 381 N/A 0
N/A N/A 21 4.4 0
N/A N/A 643 4.6 0
N/A N/A 1363 4.3 0
N/A N/A 729 N/A 0
N/A N/A 932 4.5 0
N/A N/A 426 N/A 0
37 90 460 4.7 0
61 124 861 N/A 0
N/A N/A 298 3.8 0
N/A N/A 749 3.7 0
N/A N/A 1213 4.9 0
35 65 370 N/A 0
N/A N/A 73 4.5 0
35 101 940 4.4 0
N/A N/A 172 4.6 0
N/A N/A 1 2.4 0
N/A N/A 720 4.6 0
N/A N/A 577 N/A 0
40 107 538 4.6 0
N/A N/A 421 N/A 0
N/A N/A 378 N/A 0
N/A N/A 137 4.6 0
N/A N/A 266 4.2 1
40 109 586 N/A 0
N/A N/A 580 N/A 0
N/A N/A 498 3.4 0
20 99 671 N/A 0
76 91 391 N/A 0
N/A N/A 499 4.2 0
N/A N/A 346 N/A 1
N/A N/A 111 2.8 0
47 154 622 3.9 0
21 72 702 4.3 0
N/A N/A 339 N/A 0
52 116 877 0
57 105 234 0
N/A N/A 565 N/A 0
N/A N/A 223 4.8 0
N/A N/A 432 N/A 0
N/A N/A 484 3.4 1
55 109 887 4.8 0
N/A N/A 1137 N/A 0
N/A N/A 368 N/A 0
N/A N/A 467 N/A 0
N/A N/A 380 2.4 0
N/A N/A 709 N/A 1
N/A N/A 101 3.2 0
N/A N/A 229 3.7 0
N/A N/A 80 4.2 0
N/A N/A 565 N/A 0
N/A N/A 635 4.5 0
N/A N/A 1012 3.7 0
N/A N/A 848 4.4 0
N/A N/A 859 3.2 0
N/A N/A 522 N/A 0
N/A N/A 515 N/A 0
N/A N/A 589 N/A 0
N/A N/A 355 3.8 0
N/A N/A 139 3.2 0
31 136 751 4.2 0
36 112 267 3.5 0
52 98 282 4.2 0
30 95 558 5.1 0
N/A N/A 418 3.6 0
N/A N/A 101 N/A 0
N/A N/A 567 N/A 0
N/A N/A 310 4.9 0
N/A N/A 383 4.8 0
N/A N/A 378 N/A 0
N/A N/A 1021 4.6 0
N/A N/A 586 4.3 0
N/A N/A 679 5 0
N/A N/A 503 N/A 0
N/A N/A 1158 4.1 0
N/A N/A 553 3.5 0
N/A N/A 460 3.4 0
35 101 912 4.9 0
33 99 448 3.7 0
57 151 423 N/A 0
37 89 688 4.1 0
N/A N/A 772 N/A 0
N/A N/A 287 3.3 0
N/A N/A 631 N/A 0
N/A N/A 367 N/A 0
35 77 572 3.2 0
N/A N/A 673 4 0
N/A N/A 539 N/A 0
N/A N/A 389 N/A 0
33 81 304 4 1
N/A N/A 681 N/A 0
N/A N/A 492 N/A 1
N/A N/A 259 3.5 0
N/A N/A 196 4.9 0
N/A N/A 358 4.6 0
N/A N/A 557 3.7 0
N/A N/A 230 2.3 0
N/A N/A 276 3.9 0
N/A N/A 345 N/A 0
N/A N/A 497 3 0
N/A N/A 58 4.2 0
N/A N/A 552 N/A 0
N/A N/A 343 3.4 0
N/A N/A 1006 N/A 0
N/A N/A 405 4 0
N/A N/A 667 4.3 0
42 94 639 4.1 0
40 141 544 N/A 0
27 125 283 3.3 0
N/A N/A 441 N/A 0
N/A N/A 224 3.5 0
N/A N/A 603 4 0
N/A N/A 1065 N/A 0
N/A N/A 592 4 0
N/A N/A 208 3.8 0
35 96 1006 3.7 0
N/A N/A 449 3.9 1
N/A N/A 496 N/A 0
N/A N/A 841 4.1 0
24 52 437 N/A 0
N/A N/A 500 3.7 0
N/A N/A 28 N/A 0
30 47 216 4.9 0
N/A N/A 600 N/A 0
49 119 452 3.7 0
N/A N/A 501 4.2 0
N/A N/A 431 4.9 0
N/A N/A 116 4.4 0
N/A N/A 647 4.5 0
N/A N/A 409 4.5 0
N/A N/A 479 N/A 0
N/A N/A 177 3.9 0
N/A N/A 980 5 0
N/A N/A 980 N/A 0
N/A N/A 1032 N/A 0
N/A N/A 413 3.2 0
N/A N/A 327 N/A 0
N/A N/A 745 N/A 0
N/A N/A 956 N/A 0
38 100 1231 4.1 0
N/A N/A 294 4.5 0
N/A N/A 118 N/A 0
N/A N/A 519 N/A 0
N/A N/A 338 3.4 0
30 102 212 3.1 1
N/A N/A 529 N/A 0
N/A N/A 193 2.1 0
N/A N/A 268 4 0
N/A N/A 497 3.7 0
N/A N/A 89 3.9 0
27 58 110 4 0
N/A N/A 4 2.1 1
N/A N/A 59 3.3 1
37 78 821 N/A 0
N/A N/A 777 N/A 0
N/A N/A 696 4.7 0
30 49 502 4.1 0
N/A N/A 519 3.8 0
40 108 457 4.1 0
N/A N/A 230 N/A 0
N/A N/A 359 N/A 0
N/A N/A 277 N/A 0
63 120 372 4.6 1
N/A N/A 269 N/A 0
39 84 301 3.9 0
N/A N/A 439 N/A 0
N/A N/A 325 4 0
N/A N/A 471 N/A 0
N/A N/A 207 4.3 1
N/A N/A 996 N/A 0
N/A N/A 483 3.5 0
N/A N/A 258 4.2 0
40 102 277 N/A 1
N/A N/A 629 4.5 0
N/A N/A 313 4.2 0
N/A N/A 547 N/A 0
N/A N/A 117 3.1 1
N/A N/A 527 3.6 0
32 100 315 4 1
N/A N/A 797 N/A 0
N/A N/A 614 N/A 0
N/A N/A 286 N/A 0
N/A N/A 152 4.7 0
N/A N/A 297 4.2 0
N/A N/A 392 N/A 0
N/A N/A 552 N/A 0
N/A N/A 192 4.7 0
N/A N/A 205 4.6 0
N/A N/A 202 4.3 0
N/A N/A 482 4.7 0
N/A N/A 795 4.7 0
N/A N/A 243 N/A 0
N/A N/A 497 N/A 0
N/A N/A 609 N/A 0
N/A N/A 637 N/A 0
N/A N/A 1018 N/A 0
52 110 693 N/A 0
N/A N/A 801 N/A 0
N/A N/A 465 N/A 0
N/A N/A 293 N/A 0
N/A N/A 278 2.3 0
N/A N/A 882 N/A 0
N/A N/A 364 3.6 0
N/A N/A 781 N/A 0
N/A N/A 366 4.5 0
39 71 537 4.3 0
N/A N/A 656 N/A 0
51 110 627 N/A 0
N/A N/A 138 N/A 0
N/A N/A 568 2.3 0
N/A N/A 76 N/A 0
N/A N/A 936 N/A 0
N/A N/A 410 3.6 0
22 95 112 4 0
N/A N/A 715 N/A 0
N/A N/A 250 4.8 0
N/A N/A 343 3.7 0
N/A N/A 598 N/A 0
N/A N/A 509 N/A 0
N/A N/A 298 4.4 0
N/A N/A 673 N/A 0
62 108 592 N/A 0
N/A N/A 515 N/A 0
34 103 559 4.4 0
36 132 247 N/A 0
N/A N/A 687 N/A 0
N/A N/A 404 4.2 0
N/A N/A 790 4.1 0
N/A N/A 566 N/A 0
N/A N/A 623 N/A 0
N/A N/A 328 4.3 0
N/A N/A 826 N/A 0
N/A N/A 432 3.4 0
40 106 328 4.9 0
52 135 375 N/A 0
N/A N/A 517 N/A 0
N/A N/A 728 N/A 0
20 71 42 4.2 0
N/A N/A 53 6.3 0
65 127 518 4.7 0
N/A N/A 125 4.3 0
N/A N/A 1072 3.8 0
N/A N/A 3 4.5 0
29 55 35 2.8 0
N/A N/A 691 N/A 0
N/A N/A 757 3.3 0
36 101 344 4.4 0
N/A N/A 525 3.7 0
